

CURRICULUM VITAE

Herbert Ho-fung LOONG, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM (Medicine), FASCO

EDUCATION

INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Faculty of Medicine, The University of Hong Kong, Hong Kong	MBBS (with Distinction in Surgery)	06/2003	Medicine & Surgery
Membership Examination, Royal Colleges of Physicians, United Kingdom	MRCP(UK)	03/2006	Internal Medicine
Fellow (By Examination), Hong Kong College of Physicians, Hong Kong	FHKCP	06/2010	Medical Oncology
Fellow (By Examination), Hong Kong Academy of Medicine, Hong Kong	FHKAM (Medicine)	10/2010	Internal Medicine
Clinical Research Fellowship, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada	--	12/2013	Fellowship in Drug Development
Postgraduate Diploma in Molecular & Diagnostic Pathology, The University of Hong Kong	PDipMDPath	10/2016	Molecular & Diagnostic Pathology
Fellow (By Nomination), Royal Colleges of Physicians of Edinburgh, United Kingdom	FRCP Edin	04/2018	Internal Medicine

PROFESSIONAL EXPERIENCE

Current:

Associate Professor (Clinical), Department of Clinical Oncology, The Chinese University of Hong Kong – March 2021 – Present [Conjoint appointment as Honorary Consultant, Department of Clinical Oncology, Prince of Wales Hospital, Hospital Authority Hong Kong]

Deputy Medical Director, Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong – January 2016 to Present

Board Member, Specialty Board in Medical Oncology, Hong Kong College of Physicians – July 2025 to June 2027

Member, Colorectal Cancer Screening Programme Task Force, Department of Health, Government of the Hong Kong SAR – Jan 2023 to present

Ethics Committee Member, Phase 1 Clinical Research Ethics Research Committee, Joint CUHK-NTEC Clinical Ethics Research Committee, The Chinese University of Hong Kong / Hospital Authority, Hong Kong SAR – Jan 2018 to Present

Joint Scientific Committee (JSC) Panelist, Joint Scientific Committee for Phase 1 Trials, The University of Hong Kong, The Chinese University of Hong Kong & Hospital Authority, Hong Kong, Hong Kong SAR – March 2018 - Present

Convenor, Prince of Wales Hospital / The Chinese University of Hong Kong Adult Sarcoma Multidisciplinary Tumour Board – Jan 2014 to Present

Previous:

Working Group Member, Cancer Expert Working Group (CEWG) on Cancer Prevention & Screening, Centre for Health Protection, Department of Health, Government of the Hong Kong SAR – March 2017 – July 2024

Committee Member, Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances: Certification of Clinical Trial/Medicinal Test) Committee, Department of Health, Government of the Hong Kong SAR – Jan 2018 to Dec 2023

Assistant Professor (Clinical), Department of Clinical Oncology, The Chinese University of Hong Kong – March 2014 to March 2021 – Affiliated College: CW Chu College [Conjoint Appointment as Honorary Associate Consultant, Department of Clinical Oncology, Prince of Wales Hospital, Hospital Authority Hong Kong]

Clinical Research Fellow in Experimental Therapeutics (Drug Development Program), Sarcoma Oncology and Neuro-Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada – January 2013 – December 2013

Resident Specialist & Resident, Department of Clinical Oncology, Prince of Wales Hospital, Hospital Authority of Hong Kong – July 2004 to March 2014

Intern, Departments of Medicine, Obstetrics & Gynaecology, Surgery, Queen Mary Hospital – July 2003 – March 2004, Department of Surgery, Queen Elizabeth Hospital – April 2004 – June 2004

PROFESSIONAL SOCIETIES

Fellowships:

Fellow, Hong Kong Academy of Medicine – Granted (by examination) 2010

Fellow, Hong Kong College of Physicians – Granted (by examination) 2010

Fellow, Royal College of Physicians of Edinburgh – Granted (by nomination) 2018

Memberships:

Committee Member, American Society of Clinical Oncology (ASCO) – 2004 – Present

Member, American Association of Cancer Research (AACR) – 2006 – Present

Member, European Society of Medical Oncology (ESMO) – 2004 – Present

Council Member, Hong Kong Society of Neuro-Oncology (HKNOS) – 2015 – Present

Member, Connective Tissue Oncology Society (CTOS) – 2015 – Present

Council Member, Hong Kong Cancer Therapy Society (HKCTS) – 2017 - Present

Committee Member, International Association for the Study of Lung Cancer (IASLC) – 2017 – Present Inaugural

Member, Immuno-Oncology Society of India – 2018 – Present

MAIN RESEARCH INTERESTS

- Drug Development / Experimental Therapeutics – The investigation and use of novel therapeutics in early phase clinical trials in Oncology, including clinical studies protocol development
- Sarcoma Medical Oncology – Clinical management and translational research on the management of sarcomas in adults, especially in the form of coordination of a multi-disciplinary approach b
- Thoracic Oncology / Lung Cancer – Clinical management and translational research in lung cancer, especially in the sphere of early phase clinical trials
- Neuro-Oncology – Clinical management and translational research of brain tumours in adults
- Cost-Effective Analyses & Health Economics – The assessment of burden of novel drugs to healthcare systems, especially in Hong Kong
- Medical Education – Undergraduate and postgraduate teaching, both in small groups/bedside sessions as well as larger didactic lectures

TEACHING

(1) Leadership / Coordinating Responsibilities

- Trainer, Medical Oncology Sub-specialty, Hong Kong College of Physicians, Hong Kong Academy of Medicine (November 2012 – Present)
- Specialty Board Member and Examiner, Medical Oncology Specialty Board, Hong Kong College of Physicians, Hong Kong Academy of Medicine (January 2019 – Present)
- Department Coordinator for Medical Year 4 Teaching, Department of Clinical Oncology, The Chinese University of Hong Kong (July 2019 – November 2019)
- Mentor, Global Physician-Leadership Stream (GPS), Faculty of Medicine, The Chinese University of Hong Kong

(2) Teaching Responsibilities

Medical Year 1, 2 and 3

1. Tutorial: How to raise clinical questions
2. Tutorial: Medical ethics

Medical Year 4

1. Case presentation teaching
2. Case scenario teaching
3. Bedside and clinical skills teaching

Medical Years 5 & 6

1. Case presentation teaching
2. Case scenario teaching
3. MED6 Professional Conduct Workshop
4. Bedside and clinical skills teaching
5. Mentor/supervisor during outpatient clinic attachments for medical students

Postgraduate / Non-medical student teaching

1. Lecturer and Tutor, MSc in Stroke and Clinical Neurosciences, Faculty of Medicine, The Chinese University of Hong Kong (Target audience include nurses and allied health professionals)
2. Lecturer and Tutor, Professional Diploma Programme in Advanced Nursing Practice, The Nethersole School of Nursing, The Chinese University of Hong Kong (Target audience include advanced nurses with interest in oncology nursing subspecialty)
3. Lecturer and Tutor, Diploma in Advanced Internal Medicine (AIM), Department of Medicine & Therapeutics, The Chinese University of Hong Kong (Target audience include practicing doctors in Hong Kong and regionally)
4. Lecturer, Master of Clinical Pharmacy Programme, School of Pharmacy, The Chinese University of Hong Kong (Target audience include practicing clinical pharmacists acquiring more in-depth knowledge in clinical pharmacy)

(3) Summary of Teaching Evaluation Results

Scoring of Teaching Evaluation Scores for teachings conducted in the Faculty of Medicine, The Chinese University of Hong Kong from academic year 2014/15 to 2023/24 have consistently been above the Faculty Average for both small class and large class teaching. (For further details, please refer to Teaching File)

LIST OF RESEARCH OUTPUTS OR CREATIVE WORKS

Total Published or Accepted Publications: 133 (Original Research: 94, Invited Reviews & Editorials: 39)

Citations: 7305; h-Index 36; i10-index 85; Source: Google Scholar (as accessed on 07 July 2025)

[**Bold and Underline** denotes First - or Senior-Authorship]

Published or Accepted Peer Reviewed Papers:

1. Wong, W. K. Y., Mok, K. K. S., Tsui, G. P. C., Chen, O. H., Loong, H. H. F., Chan, L. L., Yan, K., Mo, F., Lee, K. W. C., Lam, K. C., Mok, F. S. T., Johnson, D., Chen, A. C. C., Lam, B., Lee, M., Mok, T. S. K., & Li, M. S. C. CNS outcomes of osimertinib plus chemotherapy in patients with EGFR mutation positive lung cancer beyond osimertinib progression. *Clinical Lung Cancer*. 2025 May; 26(3).

2. Cho BC, Lu S, Lee MA, Song Z, Park JJ, Lim SM, Li Z, Zhao J, Richardson G, Zhang Y, Zhang J, Liu A, Loong HH, Chen C, Wang J, Shen Y, Fan Z, Chen Q, Wang H, Zhang J, Chen ZJ, Johnson ML, Mok T. D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial. *Nat Med.* 2025 Apr 29.
3. Woo PYM, Pu JKS, Li LF, Wong DKK, Hui VKH, Chan DTM, Lee MWY, Chan TKT, Ho JMK, Cheung KM, Tse TPK, Lau SSN, Chow JSW, Ko NMW, Loong, HHF, El-Helali A, Lam TC, Cheung FC, Poon WS. Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study. *J Neurooncol.* 2025 Mar 11.
4. Gautschi O, Park K, Solomon BJ, Tomasini P, Loong, HHF, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Fridodt-Moller B, Drilon A. Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. *J Clin Oncol.* 2025 Feb 21;JCO2402076.
5. Loong HHF, Sihoe ADL, Cheung DYT, Cheung YT, Lam DCL, Au JSK, Li MSC, Lim AJY, Li JYT, Brown WT, Wong MCS. Strengthening lung cancer screening in Hong Kong: policy, innovation, and collaborative approaches for early detection and improved outcomes. *Hong Kong Med J.* 2025 Feb;31(1):12-15.
6. Lam W.K.J., Lau C.S., Luk H.M., Au L.W.C., Chan G.C.P., Chan W.Y.H., Cheng S.S.W., Cheng T.H.T., Cheung L.L., Cheung Y.F., Chong J.S.C., Chu A.T.W., Chung C.C.Y., Chung K.L., Fung C.W., Fung E.L.W., Gao Y., Ho S., Hue S.P.Y., Lee C.-H., Lee T.L., Li P.H., Lo H.M., Man Lo I.F., Loong, H.H.F., Ma B.M., Ma W., Pang S.Y.Y., Seto W.-K., Siu S.W.K., So H., Tam Y.H., Tang W., Wong R.M.S., Yap D.Y.H., Yau M.L.Y., Chung B.H.Y., Lo S.-V. The implementation of genome sequencing in rare genetic diseases diagnosis: A pilot study from the Hong Kong Genome Project. *The Lancet Regional Health - Western Pacific.* 2025 Feb;55:101473.
7. Wu X, Lam CS, Hui KH, Loong, HHF, Zhou KR, Ngan CK, Cheung YT. Perceptions in 3.6 Million Web-Based Posts of Online Communities on the Use of Cancer Immunotherapy: Data Mining Using BERTopic. *J Med Internet Res.* 2025 Feb ;27:e60948.
8. Wong WKY, Mok KKS, Tsui GPC, Chen OH, Loong HHF, Chan LL, Yan K, Mo F, Lee KWC, Lam KC, Mok FST, Johnson D, Chen ACC, Lam B, Lee M, Mok TSK, Li MSC. CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression. *Clin Lung Cancer.* 2025 Jan :S1525-7304(25)00007-5.
9. Wei Y, Ma CT, Li MCH, Zhou KR, Loong HHF, Wong KC, Li CK, Cheung YT. Impact of Body Image Perception on Behavioral Outcomes in Chinese Adolescent and Young Adult Survivors of Sarcoma. *Cancer Med.* 2024 Dec;13(23):e70320.
10. Lau ACK, Chan BLH, Yeung CSK, Li LF, Chan DTM, Lee MWY, Chan TKT, Ho JMK, Cheung KM, Tse TPK, Lau SSN, Chow JSW, Ko NMW, Loong HHF, El-Helali A, Poon WS, Woo PYM. The impact of timing of temozolomide chemoradiotherapy for newly diagnosed glioblastoma on

patient overall survival: A multicenter retrospective study. *Neurooncol Adv.* 2024 Nov 12;6(1):vdae194.

11. Giani C, Salawu A, Ljevar S, Denu RA, Napolitano A, Palmerini E, Connolly EA, Ogura K, Wong DD, Scanferla R, Rosenbaum E, Bajpai J, Li ZC, Bae S, D'Ambrosio L, Bialick S, Wagner AJ, Lee ATJ, Koseła-Paterczyk H, Baldi GG, Brunello A, Lee YC, Loong HH, Boikos S, Campos F, Cicala CM, Maki RG, Hindi N, Figura C, Almohsen SS, Patel S, Jones RL, Ibrahim T, Karim R, Kawai A, Carey-Smith R, Boyle R, Taverna SM, Lazar AJ, Demicco EG, Bovee JVMG, Dei Tos AP, Fletcher C, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Gronchi A, Stacchiotti S. International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease. *Am J Surg Pathol.* 2024 Oct 28.
12. Yeung MCF, Liu APY, Wong SI, Loong HH, Shek TWH. GLI1-altered Mesenchymal Tumor - Multi-omic Characterization of a Case Series and Patient-level Meta-analysis of 167 cases for Risk Stratification. *Mod Pathol.* 2024 Oct 21:100635.
13. Lam CS, Hua R, Loong HH, Chung VC, Cheung YT. Association between fish oil and glucosamine use and mortality in patients diagnosed with cancer: the role of the Life Essential 8 score and cancer prognosis. *Nutr J.* 2024 Oct 17;23(1):124.
14. Li WHC, Lam DCL, Sin KM, Wong ELY, Wong CKH, Loong HHH, Cheung KY, Xia W, Song P, Chung JOK. Effectiveness of a self-determination theory-based smoking cessation intervention plus instant messaging via mobile application for smokers with cancer: Protocol for a pragmatic randomized controlled trial. *Addiction.* 2024 Aug;119(8):1468-1477.
15. Zhang Y, Wong CH, Hui CWC, Tse T, Yeung V, Cheung K, Tao Q, Loong HH. Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas. *Biomed Pharmacother.* 2024 Jul; 176:116895.
16. Fan Y, Drilon A, Chiu CH, Loong HHH, Siena S, Krzakowski M, Dziadziuszko R, Zeuner H, Xue C, Krebs MG. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. *Clin Lung Cancer.* 2024 Mar; 25(2):e81-e86.e4.
17. Cho BC, Chiu CH, Massarelli E, Buchschacher GL, Goto K, Overbeck TR, Loong HHH, Chee CE, Garrido P, Dong X, Fan Y, Lu S, Schwemmers S, Bordogna W, Zeuner H, Osborne S, John T. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. *Lung Cancer.* 2024 Feb; 188:107442.
18. Li MSC, Lee KWC, Mok KKS, Loong HHH, Lam KC, Mok FST, Chan LL, Lau YM, Chan KP, Ng JTY, Wong WKY, Lam BHW, Chen ACC, Lee MMP, Chen OH, Mok TSK. Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease. *JTO Clin Res Rep.* 2024 Feb; 5(4):100648.
19. Lam CS, Hua R, Au-Doung PLW, Wu YK, Koon HK, Zhou KR, Loong HH, Chung VC, Cheung YT. Association between potential supplement-drug interactions and liver diseases in patients with

- cancer: A large prospective cohort study. *Clin Nutr ESPEN*. 2023 Dec;58: 152-159.
20. Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. *N Engl J Med*. 2023 Nov 16;389(20):1839-1850
 21. Ang YLE, Zhao X, Reungwetwattana T, Cho BC, Liao BC, Yeung R, Loong, HH, Kim DW, Yang JC, Lim SM, Ahn MJ, Lee SH, Suwatanapongched T, Kongchay K, Ou Q, Yu R, Tai BC, Goh BC, Mok TSK, Soo RA. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study). *Cancers (Basel)*. 2023 Oct 16;15(20):4999.
 22. Lam CS, Hua R, Koon HK, Zhou KR, Lam TTN, Lee CP, Lin WL, Wong CL, Lau YM, Loong HH, Chung VC, Cheung YT. Can ChatGPT Provide Quality Information on Integrative Oncology? A Brief Report. *J Integr Complement Med*. 2024 Feb;30(2):196-205
 23. Lam CS, Ma CT, Li MCH, Wong CL, Loong HH, Leung AWK, Li CK, Koon HK, Cheung YT. The use of traditional, complementary and integrative medicine in Chinese adolescent and young adult patients with cancer: A multicenter cross-sectional study. *Eur J Oncol Nurs*. 2023 Oct;66: 102377.
 24. Lam TC, Cho WC, Au JS, Ma ES, Lam ST, Loong HH, Wong JWH, Wong SNM, Lee VH, Leung RC, Lau JK, Kam MT, Mok FS, Lim FM, Nyaw JS, Tin WW, Cheung KM, Chan OS, Kwong PW, Cheung FY, Poon DMC, Chik JY, Lam MH, Chan LW, Wong SC, Cao YB, Hui CV, Chen JZ, Chang JH, Kong SF, El Helali A; Precision Oncology Working Group (POWG). Consensus Statements on Precision Oncology in the China Greater Bay Area. *JCO Precis Oncol*. 2023 Jun;7: e2200649.
 25. El Helali A, Lam TC, Ko EY, Shih DJH, Chan CK, Wong CHL, Wong JWH, Cheung LWT, Lau JKS, Liu APY, Chan ASY, Loong HH, Lam STS, Chan GC, Lee VHF, Yuen KK, Ng WT, Lee AWM, Ma ESK. The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours. *Lancet Reg Health West Pac*. 2023 Apr 28; 36:100775.
 26. Yeoh, K., Wu Y, Chakraborty S, Elhusseiny G, Gondhowiardjo S, Joseph N, Lee AWM, Loong HH, Msadabwe-Chikuni SC, Tan BF, Ospina AV, Roques T, Shum HM, Yeoh EK. Global Health System Resilience during Encounters with Stressors - Lessons Learnt from Cancer Services during the COVID-19 Pandemic. *Clin Oncol (R Coll Radiol)*. 2023 Apr;35(4): e289-e300.
 27. Lam CS, Zhou K, Loong HH, Chung VC, Ngan CK, Cheung YT. The Use of Traditional, Complementary, and Integrative Medicine in Cancer: Data-Mining Study of 1 Million Web-Based Posts From Health Forums and Social Media Platforms. *J Med Internet Res*. 2023 Apr 21;25:e45408.

28. **Loong, HH**, Gupta A, Gronchi A. NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours. *Ann Surg Oncol*. 2023 May;30(5):2570-2573
29. Goldstein DA, Ginsberg GM, Hofnung-Gabbay D, De Abreu Lourenco R, **Loong HH**, Goh BC, Chan KKW, Di Maio M, Perrone F, Hall PS, Zer A, Rosenbaum E. Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors. *JAMA Netw Open*. 2023 Feb 1;6(2):e230490.
30. Cheung YT, Ma CT, Li MCH, Zhou KR, **Loong HHH**, Chan ASY, Wong KC, Li CK. Associations between Lifestyle Factors and Neurocognitive Impairment among Chinese Adolescent and Young Adult (AYA) Survivors of Sarcoma. *Cancers (Basel)*. 2023 Jan 28;15(3):799.
31. Lam CS, Koon HK, **Loong, HH**, Chung VC, Cheung YT. Koon HK, Loong HH, Chung VC, Cheung YT. Associations of dietary supplement use with all-cause and cause-specific mortality in patients diagnosed with cancer: a large prospective cohort study in the UK Biobank. *Eur J Nutr*. 2023 Mar;62(2):879-889.
32. Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, **Loong H**, Besse B. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. *J Clin Oncol*. 2023 Jan 10;41(2):385-394.
33. Woo PYM, Yau S, Lam TC, Pu JKS, Li LF, Lui LCY, Chan DTM, **Loong HHH**, Lee MWY, Yeung R, Kwok CCH, Au SK, Tan TC, Kan ANC, Chan TKT, Mak CHK, Mak HKF, Ho JMK, Cheung KM, Tse TPK, Lau SSN, Chow JSW, El-Helali A, Ng HK, Poon WS. Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period. *Neurooncol Pract*. 2022 Sep 10;10(1):50-61.
34. Georgiesh T, Aggerholm-Pedersen N, Schöffski P, Zhang Y, Napolitano A, Bovée JVMG, Hjelle Å, Tang G, Spalek M, Nannini M, Swanson D, Baad-Hansen T, Sciot R, Hesla AC, Huang P, Dorleijn D, Haugland HK, Lacambra M, Skoczylas J, Pantaleo MA, Haas RL, Meza-Zepeda LA, Haller F, Czarnecka AM, **Loong H**, Jebsen NL, van de Sande M, Jones RL, Haglund F, Timmermans I, Safwat A, Bjerkehagen B, Boye K. Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour. *Br J Cancer*. 2022 Nov;127(10):1793-1798.
35. Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong AM, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco BJ, Herráez AC, Gronchi A, Sy-Ortin T, Hohenberger P, de Baère T, Cesne AL, Helfre S, Saada-Bouزيد E, Anghel RM, Kantor G, Montero A, **Loong HH**, Vergés R, Kacso G, Austen L, Servois VF, Wardelmann E, Dimitriu M, Said P, Lazar AJ, Bovée JVMG, Péchoux CL, Pápai Z. Final Safety and Health-Related Quality of Life Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma. *Int J Radiat Oncol Biol Phys*. 2022 Nov 1;114(3):422-432.

36. Tsang THF, Wong KH, Allen K, Chan KKL, Chan MCM, Chao DVK, Cheung AN, Fan CYM, Hui EP, Ip DKM, Lam KO, Law CK, Law WL, Loong HHF, Wong KH, Wong MCS, Yeung RMW, Ying ACH, Ho RKW. Update on the Recommendations on Breast Cancer Screening by the Cancer Expert Working Group on Cancer Prevention and Screening. *Hong Kong Med J*. 2022 Apr;28(2):161-168.
37. Chan AK, Shi ZF, Li KK, Wang WW, Chen H, Chung NY, Chan DT, Poon WS, Loong HH, Liu XZ, Zhang ZY, Mao Y, Ng HK. Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. *Front Oncol*. 2022 Apr 26;12:839302
38. Cho BC, Loong HHF, Tsai CM, Teo MLP, Kim HR, Lim SM, Jain S, Olsen S, Park K. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. *Curr Oncol*. 2022 Mar 21;29(3):2154-2164.
39. Peng W, Cao L, Chen L, Lin G, Zhu B, Hu X, Lin Y, Zhang S, Jiang M, Wang J, Li J, Li C, Shao L, Du H, Hou T, Chen Z, Xiang J, Pu X, Li J, Xu F, Loong H, Wu L. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901). *Oncologist*. 2022 Mar 4;27(2):e116-e125.
40. Loong HH, Wong CKH, Chan CPK, Chang A, Zhou ZY, Tang W, Gibbs M. Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia. *JTO Clin Res Rep*. 2022 Feb 14;3(3):100290.
41. Mok FST, Tong M, Loong HH, Mok TSK. Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort. *Asia Pac J Clin Oncol*. 2022 Dec;18(6):614-624.
42. Kasper B, Baldi GG, Loong HH, Trent J. EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma. *Eur J Surg Oncol*. 2023 Jun;49(6):1133-1139.
43. Subbiah V., Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. *Clin Cancer Res*. 2021 Aug 1;27(15):4160-4167.
44. Shimizu T., Kim DW, Loong HH, Lin CC, Ng MC, Yamamoto N, Ma B, Tan DS. Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia- Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. *Asia Pac J Clin Oncol*. 2021 Aug;17(4):388-395.
45. Desai A., Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer

Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol*. 2021 May;18(5):313-319.

46. Chen TW., Pang A, Puhaindran ME, Maw MM, Loong HH, Sriuranpong V, Chang CC, Mingmalairak S, Hirose T, Endo M, Kawai A, Farid M, Tan SH, Goh WL, Quek R, Chan JCH, Leung AKC, Ngan RKC. The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium. *Cancer Sci*. 2021 Mar;112(3):1095-1104.
47. Loong HH. Wong CKH, Wei Y, Kwan SSC, Zhang Y, Tse T, Lau YM, Leung LKS, Tang GCH. Prevalence and prognostic impact of comorbidities and peripheral blood indices in sarcomas. *ESMO Open*. 2020 Nov; 5(6):e001035.
48. Loong HH. Du N, Cheng C, Lin H, Guo J, Lin G, Li M, Jiang T, Shi Z, Cui Y, Jin X, Yao J, Xing Y, Yao M, Wang K, Mok TSK, Liu L. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. *Transl Lung Cancer Res*. 2020 Oct;9(5):1759-1769.
49. Drilon A., Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2020 Aug 27;383(9):813-824.
50. Loong HH. Wong AM, Chan DT, Cheung MS, Chow C, Ding X, Chan AK, Johnston PA, Lau JY, Poon WS, Wong N. Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy? *J Clin Neurosci*. 2020 Aug;78:400-402.
51. Zhu VW., Lin YT., Kim DW., Loong HH., Nagasaka M., Tao H., Ang YLE., Ock CY., Tchekmedyian N., Ou SHI., Syn NL., Reungwetwattana T., Lin CC., Soo RA. An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1 NSCLC. *J Thorac Oncol*, 2020.
52. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020 Feb;21

53. Yu Y., Yu Y, Tse KY, Lee HHY, Chow KL, Tsang HW, Wong RWC, Cheung ETY, Cheuk W, Lee VWK, Chan WK, Wong AST, Loong HHF, Chan KKL, Ngan HYS, Cheung ANY, Ip PPC. Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases. *Mod Pathol.* 2020 Jan;33(1):138-152.
54. **Loong, HH.** Wong CKH, Leung LKS, Tan SC, Jen J, Lee MYK, Aguiar-Ibáñez R, Wang J. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. *Cost Eff Resour Alloc.* 2020 Jan 15; 18:2.
55. Heng M, Gupta A, Chung PW, Healey JH, Vaynrub M, Rose PS, Houdek MT, Lin PP, Bishop AJ, Hornicek FJ, Chen YL, Lozano-Calderon S, Holt GE, Han I, Biau D, Niu X, Bernthal NM, Ferguson PC, Wunder JS; Japanese Musculoskeletal Oncology Group (JMOG); Soft Tissue Osteosarcoma International Collaborative (STOIC). The role of chemotherapy and radiotherapy in localized extraskkeletal osteosarcoma. *Eur J Cancer.* 2020 Jan; 125:130-141
56. Felip E, de Braud FG, Maur M, Loong HH, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Tan DS. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. *J Thorac Oncol.* 2020 Mar;15(3):392-403.
57. Woo PYM, Lam TC, Pu JKS, Li LF, Leung RCY, Ho JMK, Zhung JTF, Wong B, Chan TSK, Loong HHE, Ng HK. Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. *Oncotarget.* 2019 Jun 4;10(38):3818-3826. PMID: 31217909; PMCID: PMC6557198.
58. Veitch Z, Zer A, Loong H, Salah S, Masood M, Gupta A, Bradbury PA, Hogg D, Wong A, Kandel R, Charames GS, Abdul Razak AR. A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS). *Sci Rep.* 2019 May 14;9(1):7390.
59. **Loong, HH.** Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. *Pharmacoecon Open.* 2020 Jun;4(2):235-247.
60. Chen TW, **Loong HH. *(co- first author)** Srikanthan A, Zer A, Barua R, Butany J, Cusimano RJ, Liang YC, Chang CH, Iakobishvili Z, Razak ARA, Lewin J. Primary cardiac sarcomas: A multi-national retrospective review. *Cancer Med.* 2019 Jan;8(1):104-110.

61. Lam TH, Wong KH, Chan KK, Chan MC, Chao DV, Cheung AN, Fan CY, Ho J, Hui EP, Lam KO, Law CK, Law WL, Loong HH, Ngan RK, Tsang TH, Wong MC, Yeung RM, Ying AC, Ching R. Recommendations on prevention and screening for colorectal cancer in Hong Kong. *Hong Kong Med J*. 2018 Oct;24(5):521-526.
62. Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, Lee VHF, Ma BBY, Cheng HC, Wong FCS, Loong HHF, Tong M, Poon DMC, Ahuja AT, King AD, Wang K, Mo F, Zee BCY, Chan KCA, Lo YMD. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. *J Clin Oncol*. 2018 Jul 10: JCO2018777847.
63. Lam TH, Wong KH, Chan KK, Chan MC, Chao DV, Cheung AN, Fan CY, Ho J, Hui EP, Lam KO, Law CK, Law WL, Loong HH, Ngan RK, Tsang TH, Wong MC, Yeung RM, Ying AC, Ching R. Recommendations on prevention and screening for breast cancer in Hong Kong. *Hong Kong Med J*. 2018 Jun;24(3):298-306.
64. **Loong HH**, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, Skrzypczak S, Lanman RB, Mok TSK. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia. *Clin Lung Cancer*. 2018 Sep;19(5):e601-e608.
65. Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. *Neuro Oncol*. 2018 Jun 18;20(7):897-906.
66. Tang FWK, Chan CWH, Choy YP, Loong HHF, Chow KM, So WKW. A feasibility study on using tablet personal computers for self-reported symptom assessment in newly diagnosed lung cancer patients. *Int J Nurs Pract*. 2018 Aug;24(4):e12658.
67. Ma B, Hui EP, King A, Leung SF, Kam MK, Mo F, Li L, Wang K, Loong H, Wong A, Chan CM, Chan KCA, Wong SCC, Lo YMD, Chan AT. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. *Br J Cancer*. 2018 Apr;118(8):1051-1055.
68. Lei YY, Ho SC, Cheng A, Kwok C, Lee CI, Cheung KL, Lee R, Loong HHF, He YQ, Yeo W. Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is Associated With Better Health-Related Quality of Life Among Chinese Patients With Breast Cancer. *J Natl Compr Canc Netw*. 2018 Mar;16(3):275-285.

69. Yeo W, Mo FK, Pang E, Suen JJ, Koh J, Yip CH, Yip CC, Li L, Loong HH, Liem GS. Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy. *Cancer Manag Res*. 2018 Feb 22;10:383-389.
70. To KKW, Wu WKK, Loong HHE. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy. *Eur J Pharmacol*. 2018 Mar 15;823:19-26.
71. Loong HH, Wong KH, Tse T. Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas. *ESMO Open*. 2018 Jan 3;3(Suppl 1): e000293.
72. Hui EP, Ma BBY, Loong HHE, Mo F, Li L, King AD, Wang K, Ahuja AT, Chan CML, Hui CWC, Wong CH, Chan ATC. Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study. *Clin Cancer Res*. 2018 Mar 1;24(5):1030-1037.
73. Mok ST, Kam MK, Tsang WK, Poon DM, Loong HH, Yeung WM, Yeung TY, Yu J, Wong CK. Frameless stereotactic radiosurgery for brain metastases: a review of outcomes and prognostic scores evaluation. *Hong Kong Med J*. 2017 Dec;23(6):599-608.
74. Hsieh SY, Chan DT, Kam MK, Loong HH, Tsang WK, Poon DM, Ng SC, Poon WS. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. *Hong Kong Med J*. 2017 Dec;23(6):594-8.
75. Tong CWS, Wu WKK, Loong HHE, Cho WCS, To KKW. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. *Cancer Lett*. 2017 Oct 1;405:100-110.
76. Yeo W, Mo FKF, Pang E, Suen JJS, Koh J, Loong HHE, Yip CCH, Ng RYW, Yip CHW, Tang NLS, Liem GS. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. *BMC Womens Health*. 2017 Jul 27;17(1):55.
77. Chan DT, Hsieh SY, Lau CK, Kam MK, Loong HH, Tsang WK, Poon DM, Poon WS. Ten-year review of survival and management of malignant glioma in Hong Kong. *Hong Kong Med J*. 2017 Apr;23(2):134-9.
78. Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. *J Clin Oncol*. 2016 Sep 10;34(26):3166-

74.

79. Choy CT, Wong CH, **Loong HHE**. Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg). *J Neurooncol*. 2016 Sep;129(3):579-581.
80. Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, Chan AW, Koh J, Hui EP, Loong H, Lee K, Li L, Ma B, To KF, Yu SC. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. *BMC Cancer*. 2015 May 12;15:395.
81. Ma BB, Goh BC, Lim WT, Hui EP, Tan EH, Lopes Gde L, Lo KW, Li L, Loong, H, Foster NR, Erlichman C, King AD, Kam MK, Leung SF, Chan KC, Chan AT. Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). *Invest New Drugs*. 2015 Aug;33(4):985-91.
82. Hui EP, Ma BB, Chan KC, Chan CM, Wong CS, To KF, Chan AW, Tung SY, Ng WT, Cheng AC, Lee VH, Chan SL, Loong, HH, Kam MK, Leung SF, Ho R, Mo F, Ngan RK, Chan AT. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. *Cancer*. 2015 Aug 15;121(16):2720-9.
83. Chan SL, Mo F, Johnson P, Li L, Tang N, Loong, H, Chan AW, Koh J, Chan AT, Yeo W. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2015 Oct;30(10):1529-35.
84. **Loong, HH**, Winquist E, Waldron J, Chen EX, Kim J, Palma D, Read N, Razak AR, Diaz-Padilla I, Chan K, Bayley A, Hossain M, Wang L, Chin S, Siu LL, Hope A. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. *Eur J Cancer*. 2014 Sep;50(13):2263-70.
85. Wong CH, **Loong, HH**, Hui CW, Lau CP, Hui EP, Ma BB, Chan AT. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. *Invest New Drugs*. 2013 Dec;31(6):1399-408.
86. Ma BB, Goh BC, Lim WT, Tan EH, Lopes GD, Hui EP, King AD, Lo KW, Loong, H, Li L, Foster N, Kam M, Leung SF, Erlichman C, Chan ATC. Multicenter Phase II study of MK-2206 in previously treated patients (pts) with recurrent and metastatic nasopharyngeal carcinoma (NPC): Mayo Clinic Phase II Consortium (Protocol: MC1079). *Mol Cancer Ther*. 2013 Nov;12(11). PubMed PMID: WOS:000209496800438. English.

87. Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong, H, Yu BK, Ahuja A, Chan AT. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. *Ann Oncol.* 2012 May;23(5):1287-1292.
88. Loong, HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK, Chan AT. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. *Radiother Oncol.* 2012 Sep;104(3):300-4.
89. Hui EP, Lui VWY, Hui CWC, Lau CPY, Loong, HHH, Wong CSC, Wong ECH, Chant ATC. Preclinical activity of axitinib and its associated change of serum biomarkers in nasopharyngeal carcinoma (NPC). *Cancer Res.* 2012 Apr 15;72. PubMed PMID: WOS:000209701504422. English.
90. Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon DM, Loong, HH, Yeo W, Chan AT, Mok TS, Chan HL. Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. *Liver Int.* 2012 Feb;32(2):271-8.
91. Hui EP, Ma BB, King AD, Mo F, Chan SL, Kam MK, Loong, HH, Ahuja AT, Zee BC, Chan AT. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. *Ann Oncol.* 2011 Jun;22(6):1280-1287.
92. Wong VW, Chan SL, Mo F, Chan TC, Loong, HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. *J Clin Oncol.* 2010 Apr 1;28(10):1660-5.
93. Chan SL, Mo F, Wong VW, Wong GL, Loong, HH, Chan V, Chan AT, Yeo W, Chan HL, Mok T. A scoring system in predicting the risk of hepatocellular carcinoma in chronic hepatitis B carrier. *Ejc Suppl.* 2009 Sep;7(2):366-. PubMed PMID: WOS:000270645901547. English.
94. Loong, HH, Cheung CY, Lam YK. A not-so-uncommon presentation of an uncommon disease: nasal natural killer/T-cell lymphoma. *Hong Kong Med J.* 2006 Dec;12(6):470-2. PMID: 17148803.

Published Invited Reviews and Editorials:

1. Wei Y, Xiao P, Deng W, Wong CL, Ngan CK, Tso WW, Leung AW, Loong HH, Li CK, Chan A, Cheung YT. Psychosocial challenges among Asian adolescents and young adults with cancer: a scoping review. *BMC Cancer.* 2025 Apr 24;25(1):770.
2. Wang Q, Liu Q, Ho KY, Lam KKW, Mao T, Law K, Liao K, Wang M, Gao Y, Abu-Odah H, Takemura N, Loong HHH, Yorke J. Experiences and needs of patients with sarcoma: a qualitative meta-synthesis. *Eur J Oncol Nurs.* 2025 Apr 8; 76:102890.

3. Liu J, Farrow M, Seymour L, Desai J, Loong HH, Ivy P, Koyoma T, Cook N, Blagden S, Garralda E, Massard C, Tolcher AW, Adashek JJ, Zhang L, Zhao S, Shen L, Kurzrock R, El-Deiry WS, Subbiah V, Joshua AM. Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. *J Clin Oncol*. 2025 Jan;JCO2401534.
4. De Guzman, R. B., Malik, M., Singh, N., Ho-Fung Loong, H., Mohan, A. Lung cancer in Asia: the impact of climate change. *eClinicalMedicine*. 2024 Jul; 102680.
5. Repetto M, Chiara Garassino M, Loong, HH, Lopez-Rios F, Mok T, Peters S, Planchard D, Popat S, Rudzinski ER, Drilon A, Zhou C. NTRK gene fusion testing and management in lung cancer. *Cancer Treat Rev*. 2024 Jun; 127:102733.
6. Laguna JC, García-Pardo M, Alessi J, Barrios C, Singh N, Al-Shamsi HO, et al. Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology. *Ther Adv Med Oncol*. 2024 Mar 6;16:17588359241231260.
7. Loong, HH., Shimizu, T., Prawira, A., Tan, AC., Tran, B., Day, D., Tan, DSP., Ting, FIL., Chiu, JW., Hui, M., Wilson, MK., Prasongsook, N., Koyama, T., Reungwetwattana, T., Tan, TJ., Heong, V., Voon, PJ., Park, S., Tan, IB., Chan, SL., Tan, DSW. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group. *ESMO Open*. 2023 Aug;8(4):101586.
8. Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hards J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong, HH, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. *Cancer Treat Rev*. 2023 Jan;112:102491.
9. Polintan ET, Canicula SK, Catahay JA, Lo KB, Villalona-Calero M, Loong, HH. Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. *Ther Adv Med Oncol*. 2022 Nov 15;14:17588359221137429.
10. Lau KTK, Ng L, Wong JWH, Loong, HHH, Chan WWL, Lee CH, Wong CKH. Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review. *Rev Endocr Metab Disord*. 2021 Dec;22(4):1121-1136.
11. Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin Y, Davis HM, Soldatenkova V, Sashegyi A, Lin AB, Lin BK, Loong, HH, Novello S, Arriola E, Pérol M, Goto K, Santini FC. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell

- lung cancer. *Future Oncol.* 2021 Mar;17(7):763-773.
12. **Loong, HH.** Reflecting on COVID-19: The Hong Kong Experience of Flattening the Curve Without Lockdown. *J Immunother Precis Oncol.* 2020 Aug 5;3(3):105-107.
 13. Wilding CP, **Loong, HH,** Huang PH, Jones RL. Tropomyosin receptor kinase inhibitors in the management of sarcomas. *Curr Opin Oncol.* 2020 Jul; 32(4):307-313.
 14. Wang SSY, **Loong, H,** Chung JPW, Yeo W. Preservation of fertility in premenopausal patients with breast cancer. *Hong Kong Med J.* 2020 Jun;26(3):216-226.
 15. **Loong, HH.** Developing Drugs for Sarcomas in a Brave New World. *J Immunother Precis Oncol.* 2020 Jun 5;3(2):62-63.
 16. **Loong, HH,** Hong A, Ng AWH, Lacambra MD, Chiu W, Tse T, Poon DMC, Tan T, Tong C, Yip J, Ngan R, Kumta S, Wong KC. Proceedings of the 3rd Chinese University of Hong Kong (CUHK) Sarcoma Masterclass, September 21, 2019. *J Immunother Precis Oncol.* 2020 May 11;3(2):96-98.
 17. **Loong, HH,** Li MSC, Tang GHC, Lau YM. Have We Revealed the Achilles' Heel of Brigatinib? Implications on Clinical Practice. *J Thorac Oncol.* 2020 Jul;15(7):1100-1102. doi: 10.1016/j.jtho.2020.03.026. PMID: 32593441.
 18. **Loong, HH,** Tan DSW, Shimizu T. Challenges and insights of early phase oncology drug development in the Asia-Pacific region. *Chin Clin Oncol.* 2019 Jun;8(3):26.
 19. **Loong, HH,** Blay JY, Munhoz RR. International Collaborations and Regional Challenges in Providing Specialist Multidisciplinary Sarcoma Care. *Am Soc Clin Oncol Educ Book.* 2019 Jan;39:616-623.
 20. Lau SCM, Batra U, Mok TSK, **Loong, HH.** Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. *Drugs.* 2019 Jun;79(8):823-831.
 21. **Loong, HH.** Optimal management of desmoid fibromatosis. *Hong Kong Med J.* 2018 Jun;24(3):316.
 22. Hsu WH, Yang JC, Mok TS, **Loong, HH.** Overview of current systemic management of EGFR-mutant NSCLC. *Ann Oncol.* 2018 Jan 1;29(suppl_1):i3-i9.
 23. **Loong, HH.** Fertility preservation in young cancer patients as a springboard to address the needs of this unique

24. Mok TSK, **Loong, HH**. Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer? *Lancet*. 2016 Apr 9;387(10027):1488-1490.
25. **Loong, HH**, Chan AC, Wong AC. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies. *J Cancer*. 2016 Jan 8;7(3):268-75.
26. **Loong, HH**, Mok K, Leung LK, Mok TS. Crizotinib in the management of advanced-stage non-small-cell lung cancer. *Future Oncol*. 2015;11(5):735-45.
27. Mok TS, **Loong, HH**. A REVELation in non-small-cell lung cancer treatment? *Lancet*. 2014 Aug 23;384(9944):640-2.
28. **Loong, HH**, Yeo W. Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. *Onco Targets Ther*. 2014 Apr 16;7:575-85.
29. **Loong, HH**, Mok TSK. Lung cancer: dropping bars or rising hoops--phase III outcomes of NSCLC. *Nat Rev Clin Oncol*. 2014 Jul;11(7):381-2.
30. **Loong, HH**, Chan AT. Controversies in the systemic treatment of nasopharyngeal carcinoma. *Oral Oncol*. 2014 Sep;50(9):785-90.
31. **Loong, HH**, Siu LL. Selecting the best drugs for phase I clinical development and beyond. *Am Soc Clin Oncol Educ Book*. 2013:469-73.
32. Leung L, Mok TS, **Loong, H**. Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. *Ther Adv Med Oncol*. 2012 Jul;4(4):173-81.
33. Mok TS, Zhou Q, Leung L, **Loong, HH**. Personalized medicine for non-small-cell lung cancer. *Expert Rev Anticancer Ther*. 2010 Oct;10(10):1601-11.
34. Ma BBY, Loong, H. Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. *Per Med*. 2010 Mar;7(2):121-124.
35. **Loong, HH**, Ma BB, Chan AT. Update in anti-epidermal growth factor receptor therapy in the management of metastatic colorectal cancer. *J Oncol*. 2009;2009:967920.
36. **Loong, HH**, Yeo W. Imatinib-induced interstitial lung disease and sunitinib-associated intratumour haemorrhage. *Hong Kong medical journal = Xianggang yi xue za zhi*. 2008 Dec;14(6):495-8. PubMed PMID: 19060352.
37. **Loong, HH**, Ma BB, Chan AT. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. *Hematol Oncol Clin North Am*. 2008 Dec;22(6):1267-78, x.

38. **Loong, HH.** Novel agents in the frontline management of multiple myeloma. *Hematol Oncol Stem Cell Ther.* 2008 Oct-Dec;1(4):201-9.
39. **Loong, HH.** Gastro-intestinal stromal tumours: a review of current management options. *Hong Kong medical journal = Xianggang yi xue za zhi.* 2007 Feb;13(1):61-5. PubMed PMID: 17277393.

Conference Proceedings/Abstracts:

1. Chiang AC, Olmedo Garcia ME, Carlisle JW, Dowlati A, Reguart N, Felip E, Jost PJ, Steeghs N, Stec R, Gadgeel SM, **Loong HH**, Jiang W, Hamidi A, Parkes A, Paz-Ares L. Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. *ESMO Open.* 2025 Apr; 10(4):104538.
2. **Loong, H.H.F.,** Hui, C.W.C., Yeung, V.T.Y., Cheung, K.S.Y.K., Tang, A., WONG, C-H. 79P Pre-Clinical Study of Tumor Treating Fields (TTFields) Alone or in Conjunction with Systemic Therapies in Selected Bone- and Soft-Tissue Sarcomas. *ESMO Open.* 2025 Mar; p. 104393.
3. Giani, C., Denu, R. A., Ljevar, S., Gronchi, A., Napolitano, A., Rosenbaum, E., Salawu, A., Bajpai, J., Connolly, E. A., Lee, A. T. J., Trent, J. C., Kosela-Paterczyk, H., Chia-Chen Li, Z., Ogura, K., Palmerini, E., Baldi, G. G., Brunello, A., Campos, F., Cicala, C. M., Maki, R. G., Wagner, A. J., Anelkovic, V., **Loong, H. H.,** Wong, D. D., Jones, R. L., Tap, W. D., Taverna, S. M., Lazar, A. J., Demicco, E. G., Hong, A., Bovee, J. V. M. G., Dei Tos, A. P., Fletcher, C. D. M., Baumhoer, D., Sbaragila, M., Schaefer, I. M., Miceli, R., Stacchiotti, S. Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group. *ESMO Open.* 2024 Sep; 9(9), 103689.
4. Li, W. H., Lam, D. C., Sin, K. M., Wong, E. L., Wong, C. K., Loong, H. H., Cheung, K. Y., Xia, W., Song, P., & Chung, J. O. Effectiveness of Using Risk Communication to Help Smokers with Cancer Quit Smoking: A Randomized Controlled Trial. *Journal of Clinical Oncology.* 2024 Aug; 42, no. 23_suppl 158–158.
5. Cheng Y, Loong HH, Zhou C, Nishino K, Lee DH, Lee SH, Yang JC, Liu D, Rajakumar D, Han H, Puri T, Lin AB, Goto K. Efficacy and safety of 1L selpercatinib in RET fusion-positive NSCLC: LIBRETTO-431 East Asian subgroup analysis. *J Clin Oncol.* 2024 Aug;42(23_suppl):214.
6. Girard N, Kim TM, Kim HR, Loong HH, Shinno Y, Lu S, Fang Y, Zhao J, Nishino K, Lee KH, Miao L, Sakamoto T, Felip E, Yang TY, Doooms CA, Tan DS, Le X, Brase JC, Grassi P, Goto K. Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study. *J Clin Oncol.* 2024 Jun;42(17_suppl):LBA8598.
7. Lam CS, Hua R, Loong HH, Ngan CK, Cheung YT. Association between comorbidity clusters and mortality in patients with cancer: A machine learning analysis of data from the US National Health and Nutrition Examination Survey 1999–2018. *J Clin Oncol.* 2024 Jun;42(16_suppl):11132.
8. Cassier, P., Doooms, C., Gazzah, A., Felip, E., Steeghs, N., Rohrberg, K. S., De Braud, F., Solomon, B., Schuler, M., Tan, D. S., Yamamoto, N., **Loong, H. H. F.,** Cho, B. C., Wolf, J., Lin, C. C., Negrao, M. V., Werner, L., Cui, X., Farago, A. F., & De Miguel, M. J. KontRASt-01 Update: Safety and Efficacy

of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC). *International Journal of Radiation Oncology*Biography*Physics*. 2024 Jan; 118(1), Article e4-e5.

9. **Loong, HH**, Pan, X., Chiu, C. H., Yang, S.-C., Chung, M. S.-H., de Jong, L., Groen, H. J. M., Oudkerk, M., Postma, M. J., Wong, C. K. H., & Yang, P.-C. 486P Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong's healthcare system. *Annals of Oncology*. 2023 Nov; 34, S1651—S1652.
10. Ma BBY, Johnson A, Mills Shaw KR, **Loong HHH**, Mo F, Lui RN, et al. 424p MD Anderson Cancer Center Global Precision Oncology Decision Support (GLO-pods) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK). *Annals of Oncology*. 2023 Nov;34.
11. Chen, T. W.-W., Sanfilippo, R., Jones, R. L., Schuetze, S. M., Sebio Garcia, A., Alvarez, R. M., Bui, N., Ahn, J.-H., **Loong, H. H. F.**, Yen, C.-C., Hong, J. Y., Kim, H. S., Patel, S., Bryce, R. P., Xu, F., Zhang, B., Shah, N. V., Doebele, R. C., Schwartz, G., & Gounder, M. 76MO Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas. *Annals of Oncology*. 2023 Nov;34, S1496.
12. Li, M. S., Lee, K. W. C., **Loong, H. H. F.**, Lam, K. C., Mok, F. S. T., Lau, Y. M., Chan, K. P., Mok, K. K. S., Ng, J. T. Y., Chen, A. C. C., Wong, W. K. Y., Lam, B. H. W., Chen, O. H., & Mok, T. S. K. P2.09-24 Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD. *Journal of Thoracic Oncology*. 2023 Nov; 18(11), S342.
13. Negrao, M. V., Cassier, P. A., Solomon, B., Schuler, M., Rohrberg, K., Cresta, S., Dooms, C., Tan, D. S. W., Loong, H. H.-f., Amatu, A., Assmann, K. K., Fairchild, L., Sansregret, L., Fan, L., Farago, A. F., & Cho, B. C. MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors. *Journal of Thoracic Oncology*. 2023 Nov;18(11), S117—S118.
14. **Loong, H. H. F.**, Goto, K., Solomon, B. J., Park, K., Pérol, M., Arriola, E., Novello, S., Cheng, Y., Ardizzoni, A., Mak, M., Santini, F. C., Elamin, Y. Y., Drilon, A., Wolf, J., Han, B., Han, H., Uh, M., Puri, T., Ilaria, V., & Zhou, C. LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. *Annals of Oncology*. 2023 Oct; 34, S1303.
15. Loong, H. H. F., Daniele, G., Yang, T.-Y., Leal, T. A., Goto, K., Shinno, Y., Nishino, K., Sakamoto, T., Felip, E., Ruffinelli, J. C., Gallot, N., Wang, Z., Chen, C., Brennan, B., Pu, S.-F., Kornacker, M., Grassi, P., Le, X., Tan, D. S. W., & Goh, B.-C. 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088. *Annals of Oncology*. 2023 Oct; 34, S761—S762.
16. Polintan ET, Guo Y, Ramirez-Garcia L, Lo KB, Nayak SS, **Loong, HH**, Villalona-Calero MA. Oral capecitabine or tegafur/gimeracil/oteracil as induction and adjuvant/maintenance chemotherapy in the management of stage III-IVb nasopharyngeal carcinoma: A systematic-review and meta-analysis. *J Clin Oncol*. 2023 Jun 1;41(16_suppl):e18000-e18000.
17. Cappuzzo F, Castro G, Kang JH, Wu YL, Brustugun OT, Cheema PK, Owonikoko TK, Longin AS, Boran A, Duan J, Caparica R, Loong HH. KontRASt-02: A phase III trial investigating the efficacy and

safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC. *J Clin Oncol.* 2023 Jun 1 ;41(16_suppl):TPS9144.

18. Cassier PA, Doms CA, Gazzah A, Felip E, Steeghs N, Rohrberg KS, De Braud FG, Solomon BJ, Schuler MH, Tan DS, Yamamoto N, Loong, HH, Cho BC, Wolf J, Lin CC, Negrao MV, Werner L, Cui X, Farago AF, de Miguel MJ. KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC). *J Clin Oncol.* 2023 Jun 1 ;41(16_suppl):9007.
19. Cho BC, Chiu CH, Massarelli E, Buchschacher GL, Goto K, Overbeck TR, Loong, HH, Chee CE, Garrido P, Heinzmann S, Bordogna W, Zeuner H, Osborne S, John T. Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC). *J Clin Oncol.* 2023 Jun 1;41(16_suppl):9047.
20. Cooper AJ, Drilon AE, Rotow JK, Liu SV, Gautschi O, Smith KE, Lee DH, Nagasaka M, Loong, HH, Pennell NA, Patel JD, Früh M, Solomon BJ, Pall G, Uy NF, Riess JW, Wirth LJ, Yeap BY, Gainor JF, Lin JJ. First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors. *J Clin Oncol.* 2023 Jun 1;41(16_suppl):9065.
21. Tan, D., Goto, K., Loong, HH., Yang, T.Y., Gadgeel, S., Massarelli, E., Daniele, G., Le, X.N., Shinno, Y., Murakami, H., Sakamoto, T., Ruffinelli, J.C., Lu, S., Zhang, Y.P., Kim, T.M., Brennan, B.J., Chen, C.L., Joosten, M., Wang, Z.B., Pu, S.F., Bao, W.C., Kornacker, M., Ferraldeschi, R., Grassi, P., Goh, BC. Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation. *Cancer Research.* 2023 Apr; 83(8_Supplement): CT126-CT126.
22. Rodon, J., Goyal, L., Mercade, T. M., Ikeda, M., Kondo, S., Oh, D., Bai, L., Ueno, M., Italiano, A., Papadopoulos, K., Spigel, D., Kizilbash, S. H., Cosman, R., Park, J. O., Chen, L., Yokota, T., Turk, A. A., Liao, C. Y., Shroff, R., El-Khoueiry, A., Satoh, T., Hollebecque, A., Borad, M. J., Jaeckle, K. A., Loong, HHH., Adeva, J., Yong, W. P., Zhao, J. J., Liu, H., Szpurka, A. M., Gueorguieva, I., Pradhan, K. R., XU, X. J., Harding, J.J. Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors. *Cancer Research.* 2023 Apr; 83(8_Supplement): CT098-CT098.
23. Drillon, AE., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, FG., Solomon, B., Tan, DSW., Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, SS., Puri, T., Lin, AK., Loong, HH., Besse, B. Durability of Efficacy with Selpercatinib in Patients (pts) with RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC). *Oncology Research and Treatment.* 2022 Nov; 45(SUPPL 3):150-.
24. Rajaram, R., Sholl, LM., Dacic, S., Goldman, JW., Tan, DSW., Gautschi, O., Loong, HHH., De Braud, FG., Massarelli, E., Levy, BP., Dy, GK., Kang, S., Szymczak, S., Chao, BH., Drilon, AE. LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIa RET fusion-positive NSCLC. *Journal of Clinical Oncology.* 2022 Nov; 40(16).
25. Lu S, Fan Y, Chiu CH, Yu Y, Loong, HH, Lin CC, Dong X, Li J, Zhao J, Zhang Z, Zhao N, Xu T, Hou M, Wang D, Hu X. 264P Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp non-small cell lung cancer (NSCLC). *Ann Oncol.* 2022 Nov;33:S1536.
26. Fan Y, Drilon A, Chiu CH, Bowles DW, Loong, HH, Siena S, Goto K, Krzakowski M, Ahn MJ, Murakami H, Dziadziuszko R, Zeuner H, Pitcher B, Cheick D, Krebs MG. MA13.04 Entrectinib in

Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis. *J Thorac Oncol.* 2022 Sep; 17(9):S89—S90.

27. Loong, HH, Liu T, Pattipaka T, Hong R, Smith TW, Knoll SM, Pretre V, Caparica Bitton R, Ye F, Farago A. 1181P Heterogeneity and prognostic diagnosis of KRAS-mutated population and KRAS G12C subtype among patients (pts) with advanced NSCLC (aNSCLC): A real-world study aided by machine learning approaches. *Ann Oncol.* 2022 Sep; 33:S1088.
28. Tsang S, Wong C, Kan J, Tsia K, Ng PF, Loong H, Ho JC. EP03.01-011 Prevalence of KRAS Mutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong. *J Thorac Oncol.* 2022 Sep;17(9):S242.
29. Tan DS, Shimizu T, Solomon B, Heist RS, Schuler M, Luken MJ, Gazzah A, Wermke M, Dooms C, Loong, HH, Steeghs N, Felip E, Steuer CE, van Cutsem E, Soo RA, Jaeger AC, Kim J, Xu K, Chen X, Cui X, Burks H, Farago A, Cassier PA. Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors. *Cancer Res.* 2022 Jun 15;82(12_Supplement):CT033.
30. Solomon, B., Heist, RS., Ta, DSW., Cassier, PA., Dooms, C., Van Cutsem, E., Steuer, CE., Steeghs, N., Schuler, M., Gazzah, A., Wermke, M., Felip, E., Loong, HHF., Luken, MJD., Soo, RA., Jaeger, A., Xu, K., Chen, XY., Cui, XM., Burks, H., Farago, AF., Shimizu, T. KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation. *Molecular Cancer Therapeutics.* 2021 Dec; 20(12). Abstract: LBA038.
31. Bauer, TM., Besse, B., Loong, HHF., Robinson, B., Soldatenkova, V., Muehlenbein, CE., Fridmott-Moller, B., McCoach, CE. Safety of selpercatinib for RET-altered advanced solid tumors: a post hoc analysis of LIBRETTO-001. *Cancer Research.* 2021 Jul; 81(13).
32. Schoffski, P., Cho, BC., Italiano, A., Loong, HHF., Massard, C., Rodriguez, LM., Shih, JY., Subbiah, V., verlingue, L., Andreas, K., Basson, CT., Clawson, A., Ho, PTC., Knight, S., Scheuber, A., Keegan, M. BOS172738, a Highly Potent and Selective RET Inhibitor, for the Treatment of RET-Altered Tumors Including RET-Fusion+ NSCLC and RET-Mutant MTC: Phase 1 Study Results. *Journal of Clinical Oncology.* 2021 May; 39 (15):3008–8.
33. Loong, H., Wong, C., Chan, C., Chang, A., Zhou, Z., Tang, W., Gibbs, M. Economic Impact of Next-Generation Sequencing (NGS) vs. Single-gene Testing Strategies to Detect Genomic Alterations (GAs) in mNSCLC in Asia. *Journal of Thoracic Oncology.* 2021 Mar; 16(3): S231-232.
34. Ravi, V., Wagner, M., Chen, TWW., Loong, HH., Mennel, R., Yen, CC., Clack, G., Cutler, D., Kwan, R., Chan, WK. A phase 2 study of oral paclitaxel and encequidar (oPac plus E) in the treatment of cutaneous angiosarcoma: The breast angiosarcoma subgroup. *Cancer Research.* 2021 Feb; 81(4): PS13-05.
35. Solomon BJ, Loong, HH, Summers Y, Thomas ZM, French P, Lin BK, Sashegyi A, Wolf J, Yang JCH, Drilon A. Correlation between treatment effects on overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations. *Proc Am Soc Clin Onc* 2020. Abstract No. 3588
36. Overbeck T, Siena S, Doebele RC, Shaw AT, Karapetis CC, Tan DSW, Cho BC, Kim DW, Ahn MJ, Krebs MG, Goto K, Garrido P, Farago AF, Loong, HHF, Tosi D, Barve M, Simmons BP, Ye CL, Huang XH, Drilon A. Efficacy of Entrectinib in Patients (PTS) with Solid Tumors and Central Nervous System

(CNS) Metastases: Integrated Analysis from 3 Clinical Trials. *Oncol Res Treat.* 2020 Feb;43:34-5. PubMed PMID: WOS:000517158700085. English.

37. Kwan SCS, Wong CKH, Ho C, Zhang YZ, Tse T, Lau YM, Leung LKS, Tan T, **Loong, HH**. Neutrophil-lymphocyte and platelet-lymphocyte ratios as robust prognostic markers in sarcomas: . *Annals of Oncology.* 2019 Nov;30. PubMed PMID: WOS:000503487700393.** *Loong HH as supervisor and senior author to medical student Kwan SCS who obtained Conference Merit Award for ESMO Asia 2019*
38. **Loong, HH**, Chow C, Ho K, Fung J, Koh J, Chan TC, Leung LKS, Yeo W, Ma BBY, Chan SL, Hui EP, Lee KWC, Wong ACY, Lam DCM, Wong KCW, Mok ST, To KF. Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases. *Annals of Oncology.* 2019 Nov;30. PubMed PMID: WOS:000503487700357** - *Winner of Best Poster Award at ESMO Asia Congress, 2019.*
39. Tan AC, **Loong, H**, Ho GF, Seet A, Chiam B, Cheah DQ, Tan GS, Lim KH, Yang JCH, Mok TSK, Kim DW, Tan DSW. Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG001). *Annals of Oncology.* 2019 Nov;30. PubMed PMID: WOS:000503487700361.
40. **Loong, HHE**, Wong CKH, Ho CW, Leung LKS, Tse T, Kwan SS, Lau YM. Prevalence of chemotherapy use and its impact on overall survival in patients with bone and soft tissue sarcomas: A population-based analysis of 3746 patients. *Annals of Oncology.* 2019 Oct;30:691-. PubMed PMID: WOS:000491295504344. English.
41. **Loong, HHE**, Mennel R, Wagner M, Tse T, Lau YM, Yuen CSF, Moore R, Kwan MFR, Cutler D, Kramer D, Chan WK, Ravi V. A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010). *Annals of Oncology.* 2019 Oct;30. PubMed PMID: WOS:000491295505005. English.
42. Tan A, Mok T, Kim D, Yang JC, Lee C, Soo R, Reungwetwattana T, Tan D, **Loong, H**. ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology.* 2019 Oct;14(10):S836-S7. PubMed PMID: WOS:000492162204290. English.
43. Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, Tan SWD, **Loong, H**, Bauer T, Kim YJ, Horiike A, Park K, Shah M, McCoach C, Bazhenova L, Seto T, Brose M, Pennell N, Weiss J, Matos I, Peled N, Cho BC, Ohe Y, Reckamp K, Boni V, Satouchi M, Falchook G, Akerley W, Daga H, Sakamoto T, Patel J, Lakhani N, Barlesi F, Burkard M, Zhu V, Garcia VM, Medioni J, Matrana M, Rolfo C, Lee DH, Nechushtan H, Johnson M, Velcheti V, Nishio M, Toyozawa R, Ohashi K, Song L, Han J, Spira A, De Braud F, Rohrberg KS, Takeuchi S, Sakakibara J, Waqar S, Kenmotsu H, Wilson F, Nair B, Olek E, Kherani J, Ebata K, Zhu E, Nguyen M, Yang L, Huang X, Cruickshank S, Rothenberg S, Solomon B, Goto K, Subbiah V. Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. *Journal of Thoracic Oncology.* 2019 Oct;14(10):S6-S7. PubMed PMID: WOS:000492162200010. English.
44. **Loong, HH**, Wong CK, Ho CW, Tse T, Kwan SCS, Lau YM, Leung LK. Prevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong. *Annals of Oncology.* 2019 Oct;30. PubMed PMID: WOS:000491239300207. English.
45. **Loong, HHE**. Checkpoint Inhibition and Other Immunotherapies in the Management of Sarcomas: Are We There Yet? *Annals of Oncology.* 2019 Oct;30:68-. PubMed PMID: WOS:000491239300388. English.

46. Lacambra MD, Loong, H, To KF, Feng X, Taylor G, Pleasance E, Laskin J, Marra M, Griffith J, Yeung HYM, Wong KC, Chow C, Kumta S, Ng WHA, Tse T, Tong C, Ng T. FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: Clinical and molecular pathology findings of two cases. *Annals of Oncology*. 2018 Nov;29:125-. PubMed PMID: WOS:000458082200453. English.
47. Ma BBY, van der Velden N, Mo F, Loong, HH, Siu L, Goh BC, Bang YJ, Lin CC, Desai J, Lolkema MP. Phase I investigator's perceptions to 'supersized seamless trials in oncology'. *Annals of Oncology*. 2018 Nov;29. PubMed PMID: WOS:000458082200133. English.
48. Loong, HH, Wong CKH, Leung LKS, Chan CPK, Chang A, Gibbs M. Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong. *Annals of Oncology*. 2018 Nov;29. PubMed PMID: WOS:000458082200038. English.
49. Oxnard G, Subbiah V, Park K, Bauer T, Wirth L, Velcheti V, Shah M, Besse B, Boni V, Reckamp K, Loong, H, Bazhenova L, Solomon B, Tan D, Patel J, Johnson M, Gazzah A, Mok T, Smith S, Tuch B, Ebata K, Zhu E, Nguyen M, Huang X, Cruickshank S, Rothenberg S, Drilon A. Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion plus Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2018 Oct;13(10):S349-S50. PubMed PMID: WOS:000454014500287. English
50. Drilon AE, Subbiah V, Oxnard GR, Bauer TM, Velcheti V, Lakhani NJ, Besse B, Park K, Patel JD, Cabanillas ME, Johnson ML, Reckamp KL, Boni V, Loong, HHF, Schlumberger M, Solomon B, Cruickshank S, Rothenberg SM, Shah MH, Wirth LJ. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. *Journal of Clinical Oncology*. 2018 May 20;36(15). PubMed PMID: WOS:000442916000004. English.
51. Loong, H, Yuen C, Mo F, Chan TC, Lee KWC, Chan ACY, Wong ACY, Wong KCW, Lam CM, Tong J, Wong CKH, Yeo W. Pembrolizumab in patients with advanced/metastatic acral lentiginous melanoma. *Annals of Oncology*. 2017 Nov;28:116-. PubMed PMID: WOS:000425626900364. English.
52. Loong, H, Raymond V, Chua DTT, Teo PML, Yung T, Lanman RB, Skrzypczak S, Mok TSK. Genomic profiling for advanced non-small-cell lung cancer (NSCLC) from circulating tumour DNA (ctDNA). *Annals of Oncology*. 2017 Nov;28:173-. PubMed PMID: WOS:000425626900536. English.
53. Pang A, Ngan R, Tan SH, Hirose T, Endo M, Farid M, Goh WL, Loong, HH, Mingmalairak S, Chang CC, Teo S, Maw MM, Leung AKC, Chan JC, Puhaindran ME, Kawai A, Chen WWW, Quek R, Sriuranpong V. Treatment patterns, clinical outcomes and prognostic factors of visceral angiosarcoma (V-AS): A report from the Asian Sarcoma Consortium (ASC). *Annals of Oncology*. 2017 Sep;28. PubMed PMID: WOS:000411324004023. English.
54. Chen TWW, Loong, HH *co-first authorship, Zer A, Barua R, Buttany J, Cusimano RJ, Liang YC, Chang CH, Iakobishvili Z, Razak ARA, Lewin J. Primary cardiac sarcoma (PCS): A multi-national retrospective review of clinical experience. *Annals of Oncology*. 2017 Sep;28. PubMed PMID: WOS:000411324004025. English.
55. Loong, HH, Mo F, Li L, Lee C, Lam KC, Koh J, Chiu P, Teoh A, Chan ATC, Ng E, Yeo W. Phase I/II study everolimus in combination with paclitaxel-carboplatin in patients with advanced adenocarcinoma of the stomach. *Annals of Oncology*. 2017 Sep;28. PubMed PMID: WOS:000411324001060. English.
56. Hui EP, Ma BBY, Chan KCA, Chan CML, Wong SCC, To KF, Loong, HHF, Mo FKF, Ngan RKC, Chan ATC. Examination of ERCC1 status in circulating tumor cells as a prognostic tool for patients

with nasopharyngeal carcinoma. *Cancer Res.* 2017 Jul;77. PubMed PMID: WOS:000442513301519. English.

57. To KKW, Tong WS, Wu WKK, **Loong, HHF**. PPARgamma agonists sensitize PTEN-deficient lung cancer cells resistant to EGFR tyrosine kinase inhibitors. *Cancer Res.* 2017 Jul;77. PubMed PMID: WOS:000442496700261. English.
58. Kwong TT, Wong CH, **Loong, HHF**, Chan SL. A preclinical study of the combined treatment of arginase and canavanine in pancreatic cancer. *Cancer Res.* 2017 Jul;77. PubMed PMID: WOS:000442496703163. English
59. Felip E, De Braud FG, Maur M, **Loong, HHF**, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Scott JW, Yu R, Selvaggi G, Mishra K, Lau YYY, Tan DSW. Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus) advanced non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology.* 2017 May 20;35. PubMed PMID: WOS:000411895704105. English.
60. Mok FST, Kam MKM, Tsang WK, Poon DMC, **Loong, HH**. Stereotactic Brain Radiosurgery in Lung Cancer Patients in the Era of Personalized Therapy: A Review of Outcomes and Prognostic Scores Evaluation. *J Thorac Oncol.* 2017 Jan;12(1):S1038-S. PubMed PMID: WOS:000413055802263. English.
61. Chen TWW, Pang A, Puhaindran ME, Maw MM, **Loong, HH**, Sriuranpong V, Chang CC, Teo S, Mingmalairak S, Hirose T, Endo M, Kawai A, Farid M, Tan SH, Goh WL, Quek R, Chan JC, Leung AKC, Ngan R. Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium. *Annals of Oncology.* 2016 Dec;27. PubMed PMID: WOS:000393980600501. English.
62. Quek R, **Loong, HH**, Sriuranpong V, Farid M, Tan SH, Goh WL, Mingmalairak S, Chen TWW, Chang CC, Pang A, Teo S, Puhaindran ME, Maw MM, Ngan R, Leung AKC, Chan JC, Hirose T, Endo M, Kawai A. Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC). *Annals of Oncology.* 2016 Dec;27. PubMed PMID: WOS:000393980600500. English.
63. **Loong, HH**, Wong CKH, Leung LKS, Leung MTK, Wang J, Stevinson K. Cost-effectiveness of pembrolizumab compared to ipilimumab and chemotherapy as a first line treatment for patients with advanced melanoma in Hong Kong. *Annals of Oncology.* 2016 Dec;27. PubMed PMID: WOS:000393980600404. English.

Conference Papers (as presenting author)

1. **“SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.”**
Loong, HHF, Lin Li, Lin Wu, Tae Min Kim, Arsela Prelaj, Xiaorong Dong, Hye Ryun Kim, Tsung-Ying Yang, Gennaro Daniele, Shun Lu, Yong Fang, Yuki Shinno, Liyun Miao, Nicolas Girard, Jun Zhao, Gerrina Ruiters, Virginie Aris, Rui Li, Paolo Grassi, Xiuning Le
 ASCO Annual Meeting 2025, June 2025, Chicago

2. **“Abstract CT266: D3S-001, a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in KRAS G12C inhibitor resistant non-small cell lung cancer”**
Loong, HHE, Ziming Li, Byoung Chul Cho, Jun Zhao, John Park, Zhengbo Song, Bowyer Samantha, Ki Hyeong Lee, Xiaorong Dong, Jianya Zhou, Cheng Chen, Yangbo Liu, Yandong Shen, Shaonan Wang; Zifei Fan, Qian Chen; Hui Wang, Jing Zhang, Zhi Jian Chen, Tony S. Mok, Shun Lu.
 AACR Annual Meeting 2025, April 2025, Chicago
3. **“First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC”**
 Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators.
 ESMO Congress 2023, October 2023, Spain
4. **“Cost-effectiveness of Low-dose Computerized Tomography Lung Cancer Screening in High-risk Non-smokers and Smokers in Hong Kong”**
Loong, HH, Pan, XQ., Chiu, CH., Yang, SC., Chung, MSH., de Jong, L. Groen, H., Oudkerk,, Matthijs, Postma, MJ., Wong, CKH., Yang, PC.
 World Conference on Lung Cancer (WCLC) 2023, September 2023, Singapore
5. **“Preclinical study of doxorubicin in combination with panobinostat in xenograft mice models of soft tissue sarcomas”**
 Zhang, YJ., Hui, CWC., Tse, T., Tang, GCH., Qian, T., Wong, CH., Loong, HHE.
 2022 CTOS Annual Meeting, November 2022, Canada
6. **“Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC”**
Loong, HH, Goto, K., Park, K., Ohe, Y., Nishio, M., Cho, BC., Kim, Yj., French, P., Soldatenkova, V., Tan, D.
 World Conference on Lung Cancer (WCLC) 2020, January 2021, Singapore
7. **“Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases”**
Loong, HH, Chow C, Ho K, Fung J, Koh J, Chan TC, Leung LKS, Yeo W, Ma BBY, Chan SL, Hui EP, Lee KWC, Wong ACY, Lam DCM, Wong KCW, Mok ST, To KF
 ESMO Asia Congress 2019, November 2019, Singapore** - *Winner of Best Poster Award at ESMO Asia 2019*
8. **“Prevalence of chemotherapy use and its impact on overall survival in patients with bone and soft tissue sarcomas: A population-based analysis of 3746 patients”**
Loong, HHE, Wong CKH, Ho CW, Leung LKS, Tse T, Kwan SS, Lau YM
 ESMO Congress 2019, Barcelona, Spain, September 2019
9. **“A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas(KXORAX- 010)”**
Loong, HHE, Mennel R, Wagner M, Tse T, Lau YM, Yuen CSF, Moore R, Kwan MFR, Cutler D, Kramer D, Chan WK, Ravi V.
 ESMO Congress 2019, Barcelona, Spain, September 2019

10. **“Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong”**
Loong, HH, Wong CKH, Leung LKS, Chan CPK, Chang A, Gibbs M. ESMO Asia Congress, 2018, November 2018, Singapore

11. **“Pembrolizumab in patients with advanced/metastatic acral lentiginous melanoma”**
Loong, H, Yuen C, Mo F, Chan TC, Lee KWC, Chan ACY, Wong ACY, Wong KCW, Lam CM, Tong J, Wong CKH, Yeo W.
 ESMO Asia Congress 2017, November 2017, Singapore

12. **“Genomic profiling for advanced non-small-cell lung cancer (NSCLC) from circulating tumour DNA (ctDNA)”**
Loong, H, Raymond V, Chua DTT, Teo PML, Yung T, Lanman RB, Skrzypczak S, Mok TSK. ESMO Asia Congress 2017, November 2017, Singapore

13. **“Cost-effectiveness of PDL1 based test-and-treat strategy with pembrolizumab as the 1st line treatment for NSCLC in Hong Kong”**
 Loong, H, Huang M, Wong C, Leung L, Burke T, Chandwani S, Law A, Tan SC.
 World Conference on Lung Cancer (WCLC) 2017, November 2017, Yokohama, Japan

14. **“Phase I/II study everolimus in combination with paclitaxel-carboplatin in patients with advanced adenocarcinoma of the stomach”**
Loong, HH, Mo F, Li L, Lee C, Lam KC, Koh J, Chiu P, Teoh A, Chan ATC, Ng E, Yeo W. ESMO Annual Congress 2017, October 2017, Madrid, Spain

15. **“Cost-effectiveness of pembrolizumab compared to ipilimumab and chemotherapy as a first line treatment for patients with advanced melanoma in Hong Kong”**
Loong, HH, Wong CKH, Leung LKS, Leung MTK, Wang J, Stevinson K. ESMO Asia Congress 2016, November 2016, Singapore

16. **“A Pilot Study on Intra-Tumoral Heterogeneity in Gastrointestinal Stromal Tumours”**
Loong, HH, Chow C, Ng EKW, Chan SL, Chan AWH
 2016 Connective Tissue Oncology Society (CTOS) Annual Meeting, November 2016, Lisbon, Portugal

17. **“Establishing the role of arginine deprivation in cancer treatment through pre-clinical activity of the recombinant human arginase PEG-BCT-100 in gliomas”**
Loong, HH, Choy CT, Cheung HT, Li Y, Chan A, Wong CH
 13th Asian Society for Neuro-Oncology / 9th COGNO Annual Scientific Meeting; September 2016, Sydney Australia

18. **“Preclinical evaluation of the recombinant human arginase PEG-BCT-100 leading to arginine deprivation in sarcomas”**
Loong, HH, Choy CT, Cheung HT, U KP, Wong CH
 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting, November 2015, Salt Lake City, Utah, USA

19. **“Preclinical evaluation of recombinant human arginase PEG-BCT-100 leading to arginine deprivation in gliomas”**
Loong, HH, Choy CT, Cheung HT, Li Y, Chan A, Wong CH
 20th Annual Scientific Meeting of the Society for Neuro-Oncology, November 2015, San-Antonio, TX, USA

20. **“Developing a cancer genomics digital educational tool to assess the knowledge and expectations of patients with advanced solid tumors (CADET)”**
Loong, HH, Spreafico A, Cook N, Chan KK, Krishna GD, Yu C, Kang S, Blanchette PS, Bedard PL, Razak AAR, Siu LL, 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2015, Chicago IL, USA
21. **“Preclinical evaluation of the recombinant human arginase PEG-BCT-100 leading to arginine deprivation in gliomas”**
Loong, HH, Choy CT, Cheung HT, Li Y, Chan A, Wong CH
 EORTC-EANO-ESMO Conference on Neuro-oncology 2015, March 2015, Istanbul, Turkey
22. **“Phase II study of oral ENMD-2076 administered to patients with advanced soft tissue sarcoma”**
 – *Winner of Merit Award, American Society of Clinical Oncology 2014*
Loong, HH, Blackstein M, Gupta AA, Hogg D, Culala L, Nyquist-Schultz K, Baker S, Wang L, Razak AAR
 American Society of Clinical Oncology (ASCO) Annual Meeting 2014, June 2014, Chicago, IL, USA
22. **“Phase 1 trial of nab-paclitaxel (A), cisplatin (P), and 5-fluorouracil (F) induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in patients (pts) with locoregionally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final results”** – *Winner of ECC Conference Fellowship Award (Merit Award)*
Loong, HH, Hope A, Winquist E, Hammond A, Waldron J, Diaz-Padilla I, Chen EX, Kim J, Razak AAR, Siu LL
 European Cancer Congress 2013; November 2013, Amsterdam, NL
23. **“Phase II study of oral ENMD-2076 administered to patients with advanced soft tissue sarcoma – Trial in Progress Poster”**
Loong, HH, Blackstein M, Gupta AA, Hogg D, Culala L, Nyquist-Schultz K, Baker S, Wang L, Razak AAR
 American Society of Clinical Oncology (ASCO) Annual Meeting 2013, June 2013, Chicago, IL, USA
24. **“Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma”**
Loong, HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Yu BKH, Chan ATC
 American Society of Clinical Oncology (ASCO) Annual Meeting 2011, June 2011, Chicago, IL, USA

KNOWLEDGE TRANSFER ACTIVITIES

RESEARCH

GRANTS (HELD AS PRINCIPAL INVESTIGATOR)

Competitive Research Grants (Earmarked Grants) – Held as Principal Investigator or Co-Principal Investigator

Reference No.	Title	Funding Source	Start Date	End Date	Amount (HKD)
	A Long-read and High Throughput DNA Sequencing Platform for Studying Genomic Landscapes and Metagenomics Involvement in Human Diseases [Held as Co-principal Investigator]	Research Grants Council (RGC) Collaborative Research Fund (CRF)	01 Mar 2024	28 Feb 2027	7,299,832.00
	Developing a Prognostic Model to Predict Inter- individual Trajectory of Functional Outcomes in Adolescents and Young Adults with Cancer [Held as Co-principal Investigator]	Research Grants Council (RGC) (General Research Fund)	01 Jan 2023	30 Sep 2024	498,000
	Accelerating Precision Medicine Translation: Development of the First Evidence-based Clinical Exceptional Responder Gene-Drug Sensitivity Resource for Cancer [Held as Co-principal Investigator]	Research Grants Council (Research Impact Fund)	29 Jun 20	28 Jun 25	9,996,000.00
	Clinical Development of a Urine Test for Screening of Urinary Tract Cancers [Held as Principal Investigator, in partnership with Angene Biotechnology Limited]	Innovation and Technology Commission, Government of the HKSAR	01 Jun 20	31 Dec 23	1,747,847.85

Competitive Research Grants (Held as Principal Investigator)

Reference No.	Title	Funding Source	Start Date	End Date	Amount (HKD)
	Enabling efficient clinical trial matching and enrollment for Hong Kong and GBA cancer patients through advanced Big Data analytical platform	HKEX Research Funding Scheme	01 Jun 2023	31 Aug 2025	1,000,000.00

	A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma	Rain Therapeutics, Inc.	03 Jan 2022	02 Jan 2025	590,262.37
	Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)	Daiichi Sankyo Inc.	11 Oct 2021	10 Oct 2023	751,474.40
	A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation	Novartis Pharmaceuticals (HK) Ltd	17 May 2021	16 May 2024	4,409,503.00
	LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	Eli Lilly Asia, Inc.	15 Mar 2021	14 Mar 2024	608,588.00
	A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)	Eisai Company Limited - Eisai Co., Ltd.	15 Mar 2021	14 Mar 2023	183,965.00
	Clinical Application of a Personalized Circulating Tumour DNA (ctDNA) Assay for Early Detection of Cancer Relapse	Sanomics Ltd	01 Feb 2021	31 Jan 2024	415,150.00

	A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma	Merck Sharp & Dohme (Asia) Ltd	01 Nov 2020	31 Oct 2025	1,750,019.10
	A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers	Bayer HealthCare Limited	05 Oct 2020	04 Oct 2024	508,064.53
	A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer	Arcus Biosciences, Inc - Arcus Biosciences, Inc.	22 Jun 2020	21 Jun 2023	903,383.60
	Pan-Asian Database of Advanced KRAS Mutant Non-Small-Cell Lung Carcinoma	National Cancer Centre of Singapore Pte Ltd	01 Jun 2020	31 May 2025	31,200
	A randomized open-labeled study comparing a structured titration method of immediate- and sustained-release oxycodone versus opioids titration of investigators' choice in advanced cancer patients in Hong Kong (Investigator Initiated Trial)	Mundipharma Ltd.	01 Dec 2016	On-going	100,000.00
	An Open-label Phase II Study of Pembrolizumab in East Asian Patients with Advanced/Metastatic Acral Lentiginous Melanoma (Investigator Initiated Trial)	Merck Sharp & Dohme (Asia) Ltd	01 Feb 2016	On-going	6,086,104.80
MD13915	A Feasibility Study Investigating the Presence of Intra- And Inter-tumoural Heterogeneity in Gastrointestinal Stromal Tumours and its Potential Impact on Treatment Response, Monitoring and Patients' Survival	CUHK Research Committee Funding (Direct Grants)	30 Jun 2014	29 Jun 2016	80,215.00

	A Feasibility Study Correlating Molecular Signatures between Initial Biopsies and Resected Specimens in Patients with Unresectable Gastrointestinal Stromal Tumours Who Become Resectable after Neoadjuvant Imatinib Mesylate and Exploring Potential Treatment	Hong Kong College of Physicians Young Investigator Research Grant	01 Dec 2014	30 Nov 2015	50,000.00
--	---	---	-------------	-------------	-----------

Clinical Trials Grants (Held as Principal Investigator)

Reference No.	Title	Funding Source	Start Date	End Date	Amount (HKD)
	A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Advanced or Metastatic Malignancies	Amgen Asia Holding Ltd	01 Apr 2025	1 Mar 2028	253,800.00
	A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)	Amgen Asia Holding Ltd	24 Feb 2025	23 Feb 2028	1,869,842.60
	An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	ORIC Pharmaceuticals, Inc.	15 Jan 2025	14 Jan 2028	370,318.40
	Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared with Standard of Care as First-line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harboring HER2 Tyrosine Kinase Domain Mutations	Boehringer Ingelheim International GmbH	27 Dec 2024	26 Dec 2027	1,313,666.00
	An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors	Adlai Nortye USA Inc.	01 Dec 2024	30 Nov 2027	1,406,194.00

	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAPdeletion (Master Protocol)	Amgen Asia Holding Ltd	07 Oct 2024	06 Oct 2027	1,430,949.60
	A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared with Standard of Care as a First-line Therapy in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) with HER2-activating Mutations	Bayer HealthCare Limited	02 Oct 2024	01 Oct 2027	1,499,105.50
	A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS \geq 50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)	Daiichi Sankyo Inc.	16 Oct 2023	15 Oct 2026	872,057.50
	BEAMION-Lung 1: An Open Label, Phase I Dose Escalation Trial, with Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors with HER2aberrations	Boehringer Ingelheim International GmbH	01 Aug 2023	31 Jul 2026	2,132,250.00
	A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation	D3 Bio (Wuxi) Co. Ltd	19 Jun 2023	15 Jun 2027	1,337,411.00
	A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)	Daiichi Sankyo Inc.	01 Jun 2023	31 Dec 2026	1,284,321.76
	(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors	Cogent Biosciences, Inc.	01 Jun 2023	31 Dec 2026	960,391.60

	A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer	Amgen Asia Holding Ltd	16 Jan 2023	31 May 2025	7,398,325.00
	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-null Solid Tumors	Amgen Asia Holding Ltd	19 Dec 2022	18 Dec 2025	1,059,590.00
	Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients with Advanced Dedifferentiated Liposarcoma	Boehringer Ingelheim International GmbH	27 Nov 2022	26 Nov 2026	1,353,186.00
	KontRASt-02: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects with Locally Advanced or Metastatic KRAS G12C Mutant non-small Cell Lung Cancer	Novartis Pharmaceuticals (HK) Ltd	07 Nov 2022	06 Nov 2025	1,192,665.00
	A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors	Pyramid Biosciences, Inc.	01 Nov 2022	31 Oct 2024	493,596.00
	A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)	Deciphera Pharmaceuticals, LLC	08 Aug 2022	07 Aug 2026	381,760.20
	Tumor-agnostic Precision Immunoncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	Roche Hong Kong Limited	01 Jun 2022	31 May 2025	506,648.00
	A Phase 2 Open-Label Study of Sacituzumab Govitecan (Immu-132) In Subjects with Metastatic Solid Tumors	Gilead Sciences, Inc.	01 Jun 2022	31 May 2025	815,958.80

	An Open Label, First-in-human Study of BAY 2927088 in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation	Bayer HealthCare Limited	14 Mar 2022	13 Mar 2025	1,161,557.50
	A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations	LOXO Oncology, Inc.	19 Apr 2021	18 Apr 2023	700,128.00
	ATORG-003: A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With An Epidermal Growth Factor Receptor (EGFR) Activation Mutation	National Cancer Centre of Singapore Pte Ltd	09 Nov 2020	08 Nov 2025	98,200.00
	A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination with Regorafenib in Patients with Advanced or Refractory Solid Tumors	CSStone Pharmaceuticals (Suzhou) Co Ltd	24 Aug 2020	31 Dec 2023	1,178,221.00
	A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)	Boston Pharmaceuticals, Inc	01 Jun 2020	31 May 2023	1,263,574.00
	A Phase 1/2 Dose Escalation and Dose expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors	BioAtla Inc.	20 Apr 2020	19 Apr 2025	1,251,588.00
	A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors	BioAtla Inc.	01 Mar 2020	28 Feb 2025	684,444.00
MD19347	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3	Turning Point Therapeutics, Inc.	01 Mar 2020	28 Feb 2023	631,479.20

	Rearrangements (TRIDENT-1)				
MD19666	A Phase II Single Arm Study to Investigate Tepotinib Combined with Osimertinib in MET Amplified, Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior 1st to 3rd Generation EGFR-TKIs	Merck Healthcare KGaA	02 Dec 2019	01 Dec 2022	468,637.00
MD18884	A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination with Selected Targeted Agents in EGFR Mutant NSCLC	Novartis Pharmaceuticals (HK) Ltd	25 Apr 2019	24 Apr 2022	1,660,904.00
MD18798	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Merck Sharp & Dohme (Asia) Ltd	26 Mar 2019	25 Mar 2021	2,585,311.80
MD18685	A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma	Athenex HK Innovative Ltd	26 Jul 2018	25 Jul 2023	2,048,364.00
MD17423	A Phase I Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity	LOXO Oncology, Inc.	17 Jan 2018	16 Jan 2020	950,820.81
MD16895	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Ignyta, Inc	03 Jan 2017	02 Jan 2020	239,280.00
MD16920	Screening Agreement - STARTRK-2 (Amount awarded: USD440 per screened sample) (Supplementary to MD16895)	Ignyta, Inc	08 May 2017	07 May 2019	3,432.00 per sample*

MD16831	A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Selected Advanced Solid Tumors	Bristol-Myers Squibb Pharma (HK) Ltd	08 May 2017	07 May 2019	2,135,169.00
MD16754	An Open-label, Multicenter, Phase I Study with Expansion Cohorts of Ramucirumab or Necitumumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant Non-small Cell Lung Cancer after Progression on Firstline EGFR TKI Therapy	Eli Lilly Asia, Inc	06 Mar 2017	05 Mar 2019	505,810.25
MD15618	A Multicenter Randomized, Open-label Phase II/III Study, to Compare the Efficacy of NBTXR3, Implanted as Intratumoral Injection and Activated by Radiotherapy, Versus Radiotherapy Alone in Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity a	PharmaEngine, Inc.	09 Oct 2015	08 Oct 2017	304,464.80
MD14800	A Prospective, Multicenter, Randomized, Double Blind, Placebo-Controlled, 2-Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination with FOLFIRI (Irinotecan, 5Fluorouracil and Folinic Acid) to Placebo in Combination	AB Science S.A.	19 Jan 2015	18 Jan 2018	716,979.00

Contracted Research (Held as Principal Investigator)

Reference No.	Title	Funding Source	Start Date	End Date	Amount (HKD)
MD18607	Evaluation of the Active Ingredient, Idronoxil, of NOX66, in Selected Asian Representative Cell Line, in Sarcoma, and Nasopharyngeal Carcinoma	Noxopharm Asia Ltd	01 Dec 2018	30 May 2019	225,000.00

RESEARCH GRANTS (HELD AS CO-INVESTIGATOR)

Competitive Grants (Held as Co-Investigator)

Reference No.	Title	Funding Source	Start Date	End Date	Amount (HKD)
---------------	-------	----------------	------------	----------	--------------

ITS/301/23	Development of a Novel DNA Drug for Potentiating PD-1/L1 Immunotherapy in Lung Cancer	Innovation and Technology Commission	01 May 2025	31 Oct 2026	1,399,550.00
	Efficacy of a Self-determination Theory-based Smoking Cessation Intervention plus Instant Messaging via Mobile Application for Smokers with Cancer: A Pragmatic Randomized Controlled Trial	Food and Health Bureau - Health and Medical Research Fund ((HMRF)	03 Jul 2023	02 Jan 2026	1,489,142.00
	Psychological and Functional Outcomes in Chinese Survivors of Adolescent and Young Adult (AYA) Cancer: A Pilot Study	Food and Health Bureau - Health and Medical Research Fund (HMRF)	19 Sep 2022		99,981
MD15887	Physicians' and Patients' Philosophy of Colorectal Cancer Care: A comparison of Chinese and Conventional Medicine	CUHK Research Committee Funding (Direct Grants)	30 Jun 2016	29 Jun 2017	111,000.00
MD15985	Repurposing of Clinically Approved Drugs as Autophagy Modulators to Overcome Drug Resistance to Molecular Targeted Tyrosine Kinase Inhibitors (TKI) in Treating Lung Cancer	Food and Health Bureau - Health and Medical Research Fund (HMRF)	15 Jun 2016	14 Jun 2017	100,000.00

Clinical Trials Grants (Held as Co-Investigator)

Reference No.	Title	Funding Source	Start Date	End Date	Amount (HKD)
	A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants with Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) with High PD-L1 Expression	Institut De Recherches Internationales Servier	19 Dec 2024	18 Dec 2027	1,883,712.00
	A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)	Amgen Asia Holding Ltd	16 Sep 2024	15 Aug 2026	2,239,993.00
	A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic Non-Small-Cell Lung Cancer (mNSCLC)	Gilead Sciences, Inc.	02 Sep 2024	01 Sep 2027	103,689.00
	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer	Roche Hong Kong Limited	02 Sep 2024	01 Sep 2026	424,000.40

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)	Amgen Asia Holding Ltd	12 Aug 2024	11 Aug 2026	3,329,905.70
A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIb, IIa, or Select IIb Pd-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-Based Chemotherapy	Roche Hong Kong Limited	27 May 2024	26 May 2027	1,753,784.5
LC-SHIELD (Lung Cancer Screening in High risk nonsmokers by artificial intelligence Device)	AstraZeneca Hong Kong Limited	01 Jan 2024	30 Jun 2027	6,091,550.00
Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: An Open-label, Multicenter, Single Arm Phase 2 Study	Merck Sharp & Dohme (Asia) Ltd	25 Sep 2023	24 Sep 2028	772,225.00
Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: An Open-label, Multicentre, Single Arm Phase 2 Study	Gilead Sciences, Inc.	25 Sep 2023	24 Sep 2028	3,247,805.00
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-02: Patients With Disease Progression After Receiving Systemic Treatment for Non-Small Cell Lung Carcinoma	Gilead Sciences, Inc.	16 Jan 2023	01 May 2029	232,890.00
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations	Gilead Sciences, Inc.	16 Jan 2023	01 Mar 2024	341,325.00
HERTHENA-Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy	Daiichi Sankyo Inc	22 Dec 2022	21 Dec 2026	917,112.10

	A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Tislelizumab in Patients with Select Advanced Cancers	Novartis Pharmaceuticals (HK) Ltd	16 Dec 2022	20 Jun 2025	2,679,465.00
	An Open-Label, Multicenter, Phase 2 study of Sacituzumab Govitecan Combinations in First Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations	Gilead Sciences, Inc.	04 Jul 2022	03 Jul 2026	452,512.00
	A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	Mirati Therapeutics, Inc.	04 Apr 2022	03 Apr 2025	418,966.85
	The Hong Kong Genome Project	Hong Kong Genome Institute	01 Mar 2021	28 Feb 2026	40,618,000.00
	A First In-Human, Phase 1/2 Study of CFI-402411, Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies	Treadwell Therapeutics	04 Jan 2021	03 Jan 2026	1,253,425.00
	A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma	Novocure GmbH	18 Dec 2020	17 Dec 2023	421,847.60
MD19385	A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as A Single Agent and in Combination with PDR001 in Patients with Advanced Solid Tumors	Novartis Pharmaceuticals (HK) Ltd	01 Aug 2019	29 Jul 2022	366,186.16
MD18584	A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients with Triple Negative Breast Cancer	Novartis Pharmaceuticals (HK) Ltd	25 Mar 2019	24 Mar 2022	809,008.90
MD18922	Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of GIT38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Lung Cancer (NSCLC)	G1 Therapeutics, Inc.	08 Oct 2018	07 Oct 2020	370,688.00

MD18499	A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy As First-line Treatment in Participants with HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric or Gastro	Merck Sharp & Dohme (Asia) Ltd	16 Nov 2018	15 Nov 2021	2,867,385.10
MD17375	A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Advanced or Metastatic Biliary Tract Cancer as Secondline System Therapy	ASLAN Pharmaceuticals Pte Ltd.	01 Mar 2018	28 Feb 2021	517,500.00
MD17433	Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations	Taiho Oncology, Inc.	01 Mar 2018	28 Feb 2021	661,589.20
MD17921	A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gast	Bristol-Myers Squibb Pharma (HK) Ltd	01 Feb 2018	31 Jan 2021	643,030.55
MD16698	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies	Novartis Pharmaceuticals (HK) Ltd	15 Sep 2016	14 Sep 2019	1,028,463.40
MD14328	A Phase I/II, Multicenter, Open-label Study of Oral FGF401 in Adult Patients with Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression	Novartis Pharmaceuticals (HK) Ltd	01 Apr 2015	31 Dec 2018	1,162,300.40
MD14878	A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients with Advanced Solid Tumors, with Doseexpansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breas	Novartis Pharmaceuticals (HK) Ltd	15 Jun 2015	31 Dec 2018	405,570.50
MD15392	A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)	Merck Sharp & Dohme (Asia) Ltd	01 Dec 2015	30 Nov 2018	681,652.20

MD15750	Phase 1/2 Study of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-small Cell Lung Cancer Harboring Specific Molecular Alterations	Pfizer Corporation Hong Kong Limited	21 Sep 2015	20 Sep 2018	274,851.00
MD15671	A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)	Novartis Pharmaceuticals (HK) Ltd	15 Jul 2015	31 Aug 2018	940,815.00
MD14896	A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer	F Hoffmann-La Roche Ltd	27 Dec 2014	26 Dec 2017	314,416.00
MD14910	An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Bristol-Myers Squibb Pharma (HK) Ltd	15 Dec 2014	14 Dec 2017	515,085.00
MD14958	Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine Plus Cisplatin for Intra-hepatic Cholangiocarcinoma : A Phase II Study	Sirtex Technology Pty Ltd	14 Jul 2014	13 Jul 2017	1,334,400.00
MD14808	A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with Her2+ Metastatic Breast Cancer Who Have Received Two or More Prior Her2-Directed Regimens in the Metastatic Setting (NALA)	Puma Biotechnology, Inc.	23 Jun 2015	22 Jun 2017	137,743.55

AWARDS AND HONORS

Fellow of the American Society of Clinical Oncology (FASCO), ASCO	2024
Best Poster Award, European Society of Medical Oncology Asia (ESMO Asia) Congress 2019, Singapore	2019
IASLC Foundation Cancer Care Team Award – Awarded for “Best Thoracic Cancer Care in Asia & Rest of World” 2018, International Association for the Study of Lung Cancer **Prestigious international award nominated by lung cancer patients and their caregivers. The CUHK team led by Loong HH received over 10 individual nominations and was bestowed this award for leading the best thoracic cancer care team within the geographical category of “Asia & Rest of World”	2018

Exemplary Teachers' Award, Department of Medicine & Therapeutics, The Chinese University of Hong Kong	2018
International Educational Travel Sponsorship, Hong Kong Neuro-Oncology Society (Awarded Twice)	2015 & 2016
Merit Award, American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA	2014
European Society for Medical Oncology (ESMO) Fellowship & Travel Grant for 2nd Symposium on "Signaling Pathways in Cancer" – Sitges, Barcelona, Spain	2014
Congress Fellowship (Merit Award) & Grant, European Cancer Congress 2013, Amsterdam, Netherlands	2013
European Society for Medical Oncology (ESMO) Fellowship & Travel Grant for 1st Symposium on "Signaling Pathways in Cancer" – Sitges, Barcelona, Spain	2013
Best Poster Award - The 17th Annual Scientific Symposium of the Hong Kong Cancer Institute, Hong Kong	2012
European Society for Medical Oncology (ESMO) Translational Research Unit Visit Fellowship – November 2012 at The Christie, Manchester, UK	2012
European Society for Medical Oncology (ESMO) Preceptorship in Gastrointestinal Neuroendocrine Tumours, Singapore	2012
American Society for Cancer Research (AACR) / American Society of Clinical Oncology (ASCO) Methods in Clinical Cancer Research Workshop 2010, Vail, Colorado, USA	2010
Best Intern Award, Department of Surgery, Queen Mary Hospital, The University of Hong Kong	2004

EDITORSHIP

Editorial Role:

Lung Cancer Editorial Board members, Therapeutic Advances in Medical Oncology, 2023 – Present
 Guest Editor, Journal of Immunotherapy & Precision Oncology, 2021-2022
 Editorial Board Member, BMC Cancer, January 2019 - Present
 Editorial Board Member, Journal of Immunotherapy & Precision Oncology, July 2018 - Present
 Editorial Board Member, Tumori Journal, October 2016 - Present
 Review Editor ,Head & Neck Cancer, Frontiers in Oncology, June 2012 - Present
 Editor, Hong Kong Medical Journal, May 2008 – Present

Reviewer Role:

Journal of Thoracic Oncology
 Journal of Translational Lung Cancer Research
 Journal of Clinical Oncology
 Cancer
 Annals of Oncology

Clinical Cancer Research
 Asia-Pacific Journal of Oncology
 Chinese Journal of Cancer
 Hong Kong Medical Journal
 Hematology, Oncology & Stem Cell Transplantation
 Journal of Oncology
 European Journal of Cancer

INVITED PRESENTATIONS/LECTURES

Invited Presentations/ Lectures at Conferences, Workshops, Research Institutes and Universities (Total: 124 (Up to July 2025))

1. *“The importance of multi-disciplinary team for drug development”* – ESMO TAT Asia 2025, July 2025
2. *“Incorporating patient reported outcome measurements in early phase clinical trials”* – ESMO TAT Asia 2025, July 2025
3. *“SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease”* – ASCO Annual Meeting 2025, June 2025
4. *“D3S-001, a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in KRAS G12C inhibitor resistant non-small cell lung cancer”* – AACR Annual Meeting 2025, April 2025
5. *“Combination vs. Single-Agent Therapy in Standard 1L Management for EGFR+ Lung Cancer-Pro”* – ALKclinic Plus 2025 Enhancing Outcomes in Advanced Lung Cancer, April 2025
6. *“Lung Cancer Screening Policy in the APAC Region”* – illuminate Oncology Town Hall 2.0, February 2025
7. *“Advancements and road blocks in clinical management of sarcomas”* – Hong Kong Pathology Forum 2025, January 2025
8. *“This house believes “immunotherapy is NOT beneficial in sarcomas”*– 7th masterclass of sarcoma and rare cancers, December 2024
9. *“Early detection and screening for lung cancer in the Asia Pacific region”* – ESMO Asia Congress 2024
10. *“Ensuring Accessibility, Affordability and Sustainability in Precision”* – NZSO Conference 2024, October 2024
11. *“The oncologist’s perspective on fertility preservation in female cancer patients”* - Asia Pacific Congress in Fertility Preservation, August 2024
12. *“ASCO 2024 Sarcoma Highlights”*- “From Horizon to Sunrise” Symposium 2024- Progress of Basic Science and Clinical Trials on Sarcoma, July 2024
13. *“Holistic Consideration of Costs and Benefits in the Drug Evaluation of Hong Kong”*- the 23rd Asian Conference on Clinical Pharmacy (the "ACCP 2024"), July 2024

14. “*Case Study: Selpercatinib*”- APODDC Forum 2024, July 2024
15. “*GISTs & Sarcomas Updates from ASCO 2024*”- SFA Education Session: ASCO Review 2024, June 2024
16. “*Myxoid Soft Tissue Sarcomas of the Extremities: Recurrence & Oligometastasis*” – HGSRC 4th Educational Cycle 2nd Webinar, June 2024
17. “*Giving the Right Drug to the Right Patient*” – ASCO Annual Meeting 2024, June 2024
18. “*Trends and Predictions towards 2030: How Therapies Move Through Pipelines in NSCLC*” - 2024 Asia Conversations in Oncology, April 2024
19. “*The pros and cons of PROs- PROs: We need to simplify*” – European Lung Cancer Congress 2024, March 2024
20. “*Methodological issues and usefulness (integration in regulatory agencies, health systems, pharmacy industry, etc interoperability, access)*” – ESMO Sarcoma & Rare Cancers Congress 2024, March 2024
21. “*Exploring Targeted Therapy Combinations in NSCLC*” – ESMO Global EGFR Preceptorship Programme, March 2024
22. “*Addressing Global Barriers in Manuscript Submission*” – Japanese Society of Medical Oncology Annual Meeting (JSMO2024), February 2024
23. “*Tumour-treating fields for soft tissue sarcoma*” – The 4th FORTRESS Meeting, February 2024
24. “*Novel MET, RET, NTRK inhibitors and novel targets*” – 2024 TASLC International Symposium on Treatment Advances in Lung Cancer, January 2024
25. “*Recommendations and accessibilities of next-generation sequencing in the Asia-Pacific region*” – ESMO Asia Congress 2023, December 2023
26. “*What is new in treatments for liposarcoma*” – ESMO Asia Congress 2023, December 2023
27. “*Changing the trajectory for cancer patients with liquid biopsy*” – ESMO Asia Congress 2023, December 2023
28. “*Debate #2: Drugs that have not received regulatory approvals in sarcomas should not be used to treat sarcoma patients except on a clinical trial*” – CTOS Annual Meeting 2023, November 2023
29. “*LBA4 - Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC*” – ESMO Congress 2023, October 2023
30. “*I320MO - Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088*” – ESMO Congress 2023, October 2023
31. “*Defining optimal approaches for 1L ALK+ NSCLC*” – 112 年國際胸腔聯合學術研討會, September 2023

32. *“The Past: A Brief History of Personalized Therapy in Lung Cancer”* –2023 World Conference of Lung Cancer, September 2023
33. *“Heterogeneity of NSCLC and Role of Key Driver Mutations: Current Testing Practices in Hong Kong”* –LC Summit 2023, August 2023
34. *“Using Real-World Evidence for Drug Development: The Asia Pacific Oncology Drug Development Consortium Project”* –ASCO Breakthrough, August 2023
35. *“Systemic Treatment in Soft Tissue Tumors”* –Training Course For ENT Trainees Course Programme in 2023, July 2023
36. *“Is It Necessary to Have Lung Cancer Screening in Hong Kong?”* –CME Talk (Held as Webinar), July 2023
37. *“Update on Non-Surgical Treatments of Gliomas”* –MSc in Stroke & Clinical Neurosciences Programme, Mar 2023
38. *“Are they paediatrics? Or adults? What is the difference in disease biology? Should we treat them differently?”* –1st Adolescents & Young Adults Oncology 2023 Singapore Virtual Symposium, January 2023
39. *“Looking into the Future: Is there room for combinational approaches to NTRK inhibition?”* – ESMO Virtual Advanced Course Programme, December 2022
40. *“Exploring Targeted Therapy Combinations in Non-small Cell Lung Cancer”* – 30th Annual Scientific Meeting of Hong Kong College of Radiologists, November 2022
41. *“Metastatic Non-Small Cell Lung Cancer: How Can We Improve Immunotherapy in Metastatic Disease”* – Korean Association For Lung Cancer International Conference 2022, November 2022
42. *“ASCO and ESMO Updates on STS, Desmoid, GIST”* – Israeli Sarcoma Oncology Group Live Webinar, November 2022
43. *“Challenges and opportunities for drug development in Asia”* – 34th EORTC-NCI-AACR Symposium, Spain, October 2022
44. *“Latest Advancements in Systemic Therapies in Managing Patients with Early-Stage NSCLC”* – Roche Oncology Symposium 2022, August 2022
45. *“Implications of Somatic Transformation in Germ Cell Tumours”* – VIVA-ASIA Rare Tumour Board Conference, August 2022
46. *“Agnostic biomarkers in gastrointestinal tumors: microsatellite instability, NTRK, and RET”* – 2022 Taiwan & Hong Kong Precision Oncology Summit, June 2022
47. *“Customizing the Approach to Cytotoxic Chemotherapy in Adult Sarcomas”* – American Society of Clinical Oncology Annual Meeting 2022 – Sarcoma Track Oral Abstract Discussion, June 2022
48. *“How to continue cancer care and clinical trials during COVID-19 pandemics? - Hong Kong experience”* – 2022 Taiwan Oncology Society (TOS) Mini-Symposium (Held as Webinar), May 2022

49. *“Managing advanced NSCLC: Current approach and unmet needs towards different subtypes”* – 1st SEA NSCLC Academy (Held as Webinar), May 2022
50. *“Exploring combinations for target therapies- Co-mutations”* – ATORG-APECHO Education Webinar, Apr 2022
51. *“Enhancing Drug development Through Early Phase Clinical Trials and International Collaborations”* – New Zealand Society for Oncology Conference 2021, Jan 2022
52. *“The Role of Systemic Therapies in Head and Neck Sarcomas”* – CUHK ENT conference 2021, December 2021
53. *“Precision Medicine for Elderly NSCLC Patients: Overview of Diagnostic Testing Landscape and New Treatment Approaches”* – 2nd Singapore Geriatric Cancer Symposium 2021 (Held as Webinar), Nov 2021
54. *“The Emerging Therapeutic Landscape of ALK TKIs in Advanced NSCLC”* – Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) International Conference 2021, Nov 2021
55. *“Opening new horizons: RET, NTRK, MET, HER2...”* – ESMO Congress 2021, Sep 2021
56. *“HER2 as a target: Evolution over the years”* – Changing the Destiny of HER2+ Tumour Management (Held as Webinar), Aug 2021
57. *“Induction on Adjuvant Therapy for Nasopharyngeal Carcinoma”* – American Society of Clinical Oncology Annual Meeting 2021 – Head and Neck Cancer Track Oral Abstract Discussion, June 2021
58. *“ASCO ‘s Role in Facilitating International Collaboration: Lessons From ASCO’s Asia Pacific Regional Council”* – American Society of Clinical Oncology Annual Meeting 2021 – Globalizing Cancer Care: Opportunities and Challenges Presentation, June 2021
59. *“NTRK positive patients: Can Cancer be Chronic?”* – NECTA Virtual Drug Development Meeting 2021, Mar 2021
60. *“When is the right time to use NGS-Based Liquid Biopsy in Advanced NSCLC?”* – 2020 World Conference on Lung Cancer, Jan 2021
61. *“Economic Impact of Next-Generation Sequencing (NGS) vs. Single-gene Testing Strategies to Detect Genomic Alterations (Gas) in mNSCLC in Asia”* – 2020 World Conference on Lung Cancer, Jan 2021
62. *“Developing Best Practices for the Accurate Diagnosis and Treatment of All Patients with NSCLC_ Practical Tips on Optimising Diagnosis Capabilities in the Clinic”* – 2020 World Conference on Lung Cancer, Jan 2021
63. *“Neoadjuvant and Adjuvant Therapies for Retroperitoneal Sarcomas”* – CUHK Surgical Symposium 2020. December 2020
64. *“Targeting KRAS G12C in NSCLC – Where are we in 2020?”* – Amgen JAPAC Advisory Board Meeting, November 2020

65. “*Epidemiology & Distribution of NTRK Gene Fusions in Cancers*” – ESMO Advanced Preceptorship in NTRK fusion Cancers, November 2020
66. “*Positioning Hong Kong as a Hub for Translational Research and Early Phase Clinical Trials for Lung Cancer*” – Hong Kong Immuno-Oncology Symposium, November 2020
67. “*Breaking New Grounds in Antibody Drug Conjugates*” – Hong Kong Chemotherapy Society Webinar, Feb 2021
68. “*Best of ESMO – Presentation on the CROWN Study*” – Hong Kong Chemotherapy Society Webinar, October 2020
69. “*Sarcoma Mini-Oral Abstract Discussion*” – European Society of Medical Oncology Virtual Annual Congress, September 2020
70. “*NTRK fusions in CNS Tumours*” – Regional Webinar for Hong Kong Chemotherapy Society, June 2020
71. “*The Challenge of Defining a Benchmark for Single-Arm Trials in Combination Therapies for Sarcomas*” – American Society of Clinical Oncology Annual Meeting – Sarcoma Track Oral Abstract Discussion, June 2020
72. “*Blood vs. Tissue Biopsy Battle – Comprehensive Genomic Profiling in Advanced Lung Cancer*” (to be held as Webinar), April 2020
73. “*Biomarker Detection: The Pros and Cons of Multiplex Testing in NSCLC*” – Discussions in Academic Literatures in Oncology (DIALOG) – (To be held as Webinar), April 2020 **** Invited as inaugural plenary speaker at this recurring Asia-Pacific lung cancer education event**
74. “*1st ATORG Virtual Tumour Board*” – Organized by Asian Thoracic Oncology Research Group (ATORG) – Expert commentary on *RET* fusion – (Held as Webinar), April 2020
75. “*Novel Approaches in Treating Sarcomas (Session Co-Chair)*” – 2nd FORum for Translational Research in SarcomaS (FORTRESS) Meeting, Essen, Germany, January 2020 **** Invited as the only representative from Asia** in a meeting of predominantly European and North American researchers in translational sarcoma research.
76. “*Sunrise in Tokyo Sessions – Educational Sessions of Connective Tissue Oncology Society (CTOS) Annual Meeting 2019*”, Connective Tissue Oncology Society (CTOS) Annual Meeting, Tokyo, Japan, November 2019 **** Served as inaugural educational sessions chair, coordinator and case presenter for a novel educational initiative for attendees at the primer international sarcoma annual conference spanning over 3 consecutive mornings. Preparation for this required over 6 months of coordination including invitation of speakers, assignment of topics and also submitting proposal to the CTOS Executive Committee.**
77. “*Updated Prevalence and Prognostic Impact of Co-morbidities in Sarcomas – A population-based study of 3746 patients in Hong Kong*” – Connective Tissue Oncology Society (CTOS) Annual Meeting, Tokyo, Japan, November 2019
78. “*Highs & Lows*” – *Managing Emerging Targets in NSCLC* – OncoForum Singapore, Singapore, October 2019

79. “*Systemic Therapies for Small Cell Lung Cancer (SCLC): Novel Targets and Patients’ Selection*” – 2019 World Lung Cancer Conference (WCLC) [Invited discussant], Barcelona, Spain, September 2019
80. “*The Molecular Biology of Sarcomas and New Trends of Therapy*” – Soft Tissue Expert Seminar, Bangalore, India, August 2019
81. “*ATORG-003 – Dacomitinib with or without dose titration as first-line therapy for metastatic EGFR mutation non-small cell lung cancer (NSCLC)*” - The 2019 Asian Thoracic Oncology Research Group (ATORG) Scientific Forum, Seoul, Korea, July 2019
82. “*Addressing Challenges of Rare Molecular Subsets in Asia*” – The 2019 Asian Thoracic Oncology Research Group (ATORG) Scientific Forum, Seoul, Korea, July 2019
83. “*Prevalence and Prognostic Impact of Co-morbidities in Sarcomas – A population-based study of 3746 patients in Hong Kong*” – Japan Society of Medical Oncology (JSMO) Annual Meeting 2019, Kyoto, Japan, July 2019
84. “*Rare Cancer in Asia: Current Status and Construction of Medical Network – The Hong Kong Experience*” – Japan Society of Medical Oncology (JSMO) Annual Meeting 2019, Kyoto, Japan, July 2019
85. “*Checkpoint Inhibition and Other Immunotherapies in the Management of Sarcomas – Are We There Yet?*” – Japan Society of Medical Oncology (JSMO) Annual Meeting 2019, Kyoto, Japan, July 2019
86. “*When Radiotherapy Meets Immunotherapy in Melanomas and Sarcomas*” – Hong Kong Stereotactic Body Radiotherapy (SBRT) Society Meeting, June 2019
87. “*Updates in the Systemic Management in Soft Tissue Sarcomas*” – Indonesian Society of Surgical Oncology Annual Meeting, Jakarta, Indonesia, June 2019
88. “*Sarcoma Care and Networks in Asia – Challenges & Opportunities*” – American Society of Clinical Oncology (ASCO) Annual Meeting 2019, Chicago, IL, USA ****Role as invited speaker, as well as Educational Track Chair for ASCO 2019 which included tasks of being corresponding and senior author of peer reviewed article submitted and published in ASCO Education Book 2019 [Loong HH, Blay JY, Munhoz RR. *Am Soc Clin Oncol Educ Book* 2019; PMID: 31099628]**
89. “*Liquid biopsy in early phase clinical trials*” – East Asia Oncology Phase 1 Conference, organized by National Taiwan University Hospital, Taiwan, April 2019
90. “*Liquid vs. Tissue-based Next Generation Sequencing – When to Use? How to Choose?*” – Lung Cancer Club (organized by Roche Pharmaceuticals), Hong Kong, March 2019
91. “*Opportunities, Developments & Infrastructure for Early Phase Clinical Trials in Hong Kong – Perspectives from HKU and CUHK*” – Drug Development Meeting 2019, New South Wales Early Phase Clinical Trials Alliance (NECTA), Sydney, Australia, March 2019
92. “*Immunotherapy in sarcoma and rare tumours: A science of uncertainty and an art of probability!*” – 1st Immuno-Oncology Society of India Congress / Tata Memorial Hospital, Mumbai, India, March 2019

93. *“The role of Immunotherapy Agents in the Management of Soft Tissue Sarcomas”* – Eisai ESCON Asian Conference, Busan, Korea, January 2019
94. *“The role of systemic therapy in retroperitoneal sarcomas”* – ESMO Asia Conference 2018, November 2018, Singapore
95. *“Checkpoint inhibition & other immunotherapies in the management of sarcomas – are we there yet?”* – Immuno-Oncology Hong Kong 2018, Hong Kong, November 2018
96. *“Clinical utilities & outcomes of Guardant360 in Asian Patients”* – Japan Cancer Association Annual Conference, Osaka, Japan, September 2018
97. *“The role of systemic therapies in Head & Neck Cancer”* – American Society of Clinical Oncology (ASCO) MCMC Programme, Baku, Azerbaijan, September 2018
98. *“Advances in molecular biology of soft tissue sarcomas and current trends in therapy”* – Eisai Precision Oncology Symposium – Chennai, India and Delhi, India (2 talks) – August 2018
99. *“Implications of molecular diagnostics in drug development and clinical management of adult patients with brain tumours”* – Molecular Brain Tumour Course, CUHK & International Academy of Pathology, May 2018
100. *“Controversies and consensus of neoadjuvant chemotherapy in soft tissue sarcomas”* – ESMO Asia 2017, Singapore, November 2017
101. *“Latest updates in the management of ALK-positive Non-small cell lung cancer”*, Department of Respiratory Medicine, University of Malaya, Kuala Lumpur, Malaysia, September 2017
102. *“Optimal management of gastrointestinal stromal tumours (GISTs)”*, Philippines Society for Medical Oncology Annual Conference, Manila, Philippines, August 2017
103. *“Phase I Oncology Clinical Trials Development in Hong Kong”* – National Cancer Center Japan, Tokyo, Japan 2017
104. *“Epidemiology & Optimal Treatment Strategies for Angiosarcomas – A report by the Asian Sarcoma Consortium”*, Chinese Sarcoma Association Conference, Shanghai, China, June 2017
105. *“Sarcomas”* – Public Education Talk (in Cantonese) at Hospital Authority Headquarters, Hong Kong SAR, April 2017
106. *“Developing phase I oncology clinical trials in Hong Kong” State Key Laboratory Summit, Hong Kong SAR, April 2017*
107. *“Precision Oncology in Sarcomas – STARTRK2: Basket Global Study”* – Japan Society of Oncology, JSA Symposium, Tokyo, Japan December 2016
108. *“Immunotherapy in the Not-so-common Cancers”* – 1st Immuno-Oncology Hong Kong Conference, Hong Kong November 2016
109. *“Medical treatment for sacral chordomas – ‘please give us some good news!’”* – 4th Singapore Sarcoma Symposium, November 2016, Singapore

110. *“Approach to systemic treatment of soft-tissue sarcomas – simplifying a complex disease”* – Philippines Society of Medical Oncology Annual Conference, November 2016, Manila, Philippines
111. *“Precision Oncology in Sarcomas”* – MD Anderson Global Academic Programs Conference, March 2014, Sao Paulo, Brazil
112. *“Novel Treatment Strategies in Gliomas”* – Multidisciplinary Management of Brain Tumours in Children and Adults, Hospital Authority Commissioned Training, January 2016, Hong Kong
113. *“The “Master Organ” Deserves Smarter Clinical Trials - Drug Development in High Grade Gliomas”* – BRAIN 2016, January 2016, Hong Kong
114. *“A ‘gist’ in the management of patients with advanced gastrointestinal stromal tumours”* – Hong Kong Society for Clinical Oncology, December 2015, Hong Kong
115. *“Antibody-drug-conjugates – A new wave of cancer drugs”* European Society of Medical Oncology (ESMO) Asia Congress 2015, December 2015, Singapore
116. *“Developmental therapeutics – oral abstract discussion”,* ESMO Asia Congress 2015, December 2015, Singapore
117. *“Advanced soft tissue sarcoma – The dilemmas of a rare & heterogeneous disease”* – Symposium organized by Novartis Hong Kong, October 2015, Hong Kong
118. *“Clinical trials in gliomas – Challenges & opportunities in Hong Kong”* – Chinese Society of conference Neurooncology (CSNO)-Society of Neuro-oncology (SNO) Joint Meeting, March 2015, Guangzhou, China
119. *“Treatment of gliomas – emerging role for a medical oncologist”* – BRAIN 2015, February 2015, Hong Kong
120. *“Updates in the management of nasopharyngeal carcinoma”* – ASCO Multidisciplinary Cancer Management Course 2014, November 2014, Manila, Philippines
121. *“Train-the-trainer – Communications skills workshop”* – ASCO Multidisciplinary Cancer Management Course 2014, November 2014, Manila, Philippines
122. *“Beyond cytotoxic chemotherapies for advanced soft-tissue sarcomas – Future perspectives”* – Oncology Symposium 2014 (organized by Glaxo-Smith-Kline, Hong Kong), August 2014, Hong Kong
123. *“Beyond cytotoxic chemotherapies for sarcomas”* – Best of ASCO 2014 in China – July 2014, Guangzhou, China
124. *“Have we gotten the gist of GISTs yet? – 12+ years on”* – Best of ASCO 2014 in China – July 2014, Guangzhou, China

CONFERENCE ORGANIZATION

- Member – Scientific Committee, ESMO Targeted Anticancer Therapies Asia Congress 2025, HKSAR, China, July 2025
- Track Co-chair –Developmental and precision medicine, Scientific Committee, ESMO Asia Congress 2024, Singapore, December 2024
- Conference Chair – The 6th CUHK Sarcoma Masterclass 2024, Hong Kong, June 2024
- Program Chair – Connective Tissue Oncology Society Annual Meeting 2023 (CTOS 2023), Dublin, Ireland, November 2023
- Member, Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy, Programme Committee, IASLC 2023 World Conference on Lung Cancer, Singapore, September 2023
- Member – Advisory Committee, ASCO Breakthrough 2023, Yokohama, Japan, August 2023
- Session Chair – Oral Abstract Session, Sarcoma Track, American Society of Clinical Oncology (ASCO) Annual Meeting 2023, Chicago, IL, USA, June 2023
- Conference Chair – The 5th CUHK Sarcoma Masterclass 2022, Hong Kong, October 2022
- Track Leader – Sarcoma Education Track, American Society of Clinical Oncology (ASCO) Annual Meeting 2023, Chicago, IL, USA, June 2022- May 2023
- Scientific Program Committee Member – Sarcoma Education Track, American Society of Clinical Oncology (ASCO) Annual Meeting 2022, Chicago, IL, USA, June 2022
- Panel Members – APODDC Board Meeting 2021, December 2021
- Organizing Committee Member – 2nd Breakthrough Conference, American Society of Clinical Oncology, Yokohama, Japan, August 2022
- Session Chair – Globalizing Cancer Care: Opportunities and Challenges, American Society of Clinical Oncology Annual Meeting 2021, June 2021
- Conference Chair – 4th CUHK Sarcoma Masterclass, March 2021
- Scientific Committee Member – “Metastatic NSCLC track” European Society for Medical Oncology (ESMO) Congress 2021, Paris, France, September 2021
- Organizing Committee Member, 1st Breakthrough Conference, American Society of Clinical Oncology (ASCO), Bangkok, Thailand, October 2019
- Session Chair, Sarcoma Education Track, American Society of Clinical Oncology (ASCO) Annual Meeting 2019, Chicago, IL, USA, June 2019
- Scientific Committee Chair, Melanoma & Sarcoma Track, European Society of Medical Oncology (ESMO) Asia Congress 2018, Singapore, November 2018

- Scientific Committee Member, Immuno-Oncology Hong Kong 2018 / 21st Annual Scientific Meeting of the Hong Kong Cancer Institute, November 2018
- Chief Organizer and Conference Chair, 2nd CUHK Masterclass in Early Phase Clinical Trials, November 2018
- Chief Organizer and Conference Chairman, 2nd CUHK Sarcoma Masterclass, September 2018
- Faculty and Conference Organizer, American Society of Clinical Oncology (ASCO) Multidisciplinary Cancer Management Course, Azerbaijan, October 2018
- Faculty and Conference Organizer, 1st Singapore Sarcoma Preceptorship Programme, November 2017
- Chief Organizer and Faculty Chairman, 1st CUHK Sarcoma Preceptorship Programme, June 2017
- Scientific Committee Member, Immuno-Oncology Hong Kong 2016 / 21st Annual Scientific Meeting of the HK Cancer Institute, Hong Kong, November 2016
- Organizing Committee Member, Multispecialty Medical MEGA Conference 2016, Hong Kong, April 2016
- Scientific Committee Member, 19th Annual Scientific Meeting of the Hong Kong Cancer Institute, Hong Kong, November 2014
- Scientific Committee Member, American Society of Clinical Oncology (ASCO) Multidisciplinary Management Course (MCMC), Manila, Philippines, November 2014

INTERNATIONAL, REGIONAL AND LOCAL COLLABORATIONS

1. Dr. Carlos KH Wong, Department of Family Medicine & Primary Care, The University of Hong Kong

Background:

Collaborations with Dr. Carlos KH Wong (health economist and biostatistician) in various health economics projects as well as ‘big-data’ epidemiological analyses.

Output(s):

- Projects and publications including health economics analyses and epidemiological studies

Representative Publication(s):

- **Loong HH**, Wong CKH, Leung LKS, Tan SC, Jen JS, Lee MYK, Aguiar-Ibanez R, Wang JS. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. *Cost Effect Resour A*. 2020 Jan 15;18(1). PubMed PMID: WOS:000513615800001. English
- **Loong HHE**, Wong CKH, Ho CW, Leung LKS, Tse T, Kwan SS, Lau YM. Prevalence of chemotherapy use and its impact on overall survival in patients with bone and soft tissue sarcomas: A population-based analysis of 3746 patients. *Annals of Oncology*. 2019 Oct;30:691-. PubMed PMID: WOS:000491295504344. English.

- **Loong HH**, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. *Pharmacoecon Open*. 2019 Sep 17. PubMed PMID: 31531842. Epub 2019/09/19.
- **Loong HH**, Wong CK, Ho CW, Tse T, Kwan SCS, Lau YM, Leung LK. Prevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong. *Annals of Oncology*. 2019 Oct;30. PubMed PMID: WOS:000491239300207. English.

2. AsiaOne – Asian Oncology Phase 1 Consortium

Background:

Members (and representatives) of AsiaOne include 5 prominent phase 1 oncology clinical trials centres in the Asia-Pacific Region: (1) Department of Clinical Oncology, The Chinese University of Hong Kong (Dr. Herbert H. Loong), (2) National Cancer Center Hospital, Tokyo Japan (Dr. Toshio Shimizu), (3) National Cancer Centre Singapore (Dr. Daniel SW Tan), (4) Seoul National University Hospital, South Korea (Dr. Dong-Wan Kim), (5) National Taiwan University Hospital, Taiwan (Dr. Josh CC Lin).

Output(s):

- Organization of regular educational meetings for clinical investigators and clinical trials personnel in the Asia-Pacific region
- Solicitation of multi-centre oncology clinical trials

Representative Publication(s):

- **Loong HH**, Tan DSW, Shimizu T. Challenges and insights of early phase oncology drug development in the Asia-Pacific region. *Chinese Clinical Oncology*. 2019 Jun;8(3). PubMed PMID: WOS:000473300900005. English.
- Toshio Shimizu, Dong-Wan Kim, Herbert H Loong, Chia-Chi Lin, Matthew Ch Ng, Noboru Yamamoto, Brigitte Ma, Daniel Sw Tan (2021). Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. *Asia Pac J Clin Oncol*. 2021 Aug;17(4):388-395. doi: 10.1111/ajco.13510. Epub 2021 Jan 27

3. Asia Sarcoma Consortium (ASC)

Background:

Members of the ASC include oncologists and surgeons from over 14 high-volume cancer centres within the Asia Pacific Region with special interests in sarcoma clinical management and research. Prominent members within the group include Dr. Herbert H. Loong of The Chinese University of Hong Kong, A/Prof (Adjunct) Richard Quek of National Cancer Centre Singapore/Duke-NUS Medical School, and Dr. Tom Wei-Wu Chen of National Taiwan University Hospital, Taiwan.

Output(s):

- Organization of regular educational meetings for trainee clinicians who are interested in sarcoma management in the Asia Pacific region, including the annual Singapore Sarcoma Preceptorship Programme and the Singapore Sarcoma Pathology Preceptorship
- Epidemiological research in sarcomas in Asia

Representative Publication(s):

- Quek R, Loong HH, Sriuranpong V, Farid M, Tan SH, Goh WL, Mingmalairak S, Chen TWW, Chang CC, Pang A, Teo S, Puhaindran ME, Maw MM, Ngan R, Leung AKC, Chan JC, Hirose T, Endo M, Kawai A. Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC). *Annals of Oncology*. 2016 Dec;27. PubMed PMID: WOS:000393980600500. English.
- Chen TWW, Pang A, Puhaindran ME, Maw MM, Loong HH, Sriuranpong V, Chang CC, Teo S, Mingmalairak S, Hirose T, Endo M, Kawai A, Farid M, Tan SH, Goh WL, Quek R, Chan JC, Leung AKC, Ngan R. Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium. *Annals of Oncology*. 2016 Dec;27. PubMed PMID: WOS:000393980600501. English.
- Pang A, Ngan R, Tan SH, Hirose T, Endo M, Farid M, Goh WL, Loong HH, Mingmalairak S, Chang CC, Teo S, Maw MM, Leung AKC, Chan JC, Puhaindran ME, Kawai A, Chen WWW, Quek R, Sriuranpong V. Treatment patterns, clinical outcomes and prognostic factors of visceral angiosarcoma (V-AS): A report from the Asian Sarcoma Consortium (ASC). *Annals of Oncology*. 2017 Sep;28. PubMed PMID: WOS:000411324004023. English.

4. Asian Thoracic Oncology Research Group (ATORG)

Background:

Members of ATORG include active thoracic oncology clinicians and researchers of the Asia-Pacific region. Prof. Tony S.K. Mok and Dr. Herbert H. F. Loong (The Chinese University of Hong Kong) are key members within this collaborative group.

Output(s):

- Multi-centre clinical and translational research projects in lung cancer
- Educational programmes for clinicians and clinical trials personnel in the Asia-Pacific region with interests in thoracic oncology

Representative Publication(s):

- Tan A, Kim D, Baisamut (Reungwetwattana) T, Ni LY, Ho G, Tho LM, Prasongsook N, Lee S, Mok T, Tan D, Loong HH. 362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial. *Annals of Oncology*. 2022 Nov;33(9):S1582-S1583.
- Tan AC, Loong HH, Ho GF, Seet A, Chiam B, Cheah DQ, Tan GS, Lim KH, Yang JCH, Mok TSK, Kim DW, Tan DSW. Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001). *Annals of Oncology*. 2019 Nov;30. PubMed PMID: WOS:000503487700361. English.
- Tan A, Mok T, Kim D, Yang JC, Lee C, Soo R, Reungwetwattana T, Tan D, Loong HH. ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology*. 2019 Oct;14(10):S836-S7. PubMed PMID: WOS:000492162204290. English.

5. Asia Pacific Oncology Drug Development Consortium (APODDC)

Background:

APODDC was formed in 2021 across Asia-Pacific region to create an interactive platform to foster education and collaboration between key stakeholders of oncology drug development within the Asia-Pacific Region, ultimately providing access to patients. Executive Committee members within the group include Dr. Herbert H. Loong of The Chinese University of Hong Kong, Dr. Daniel S. W. Tan of National Cancer Centre Singapore, and Dr. Dr Toshio Shimizu of National Cancer Center Hospital, Japan.

Output(s):

- To develop interests and insights in oncology drug development in the Asia-Pacific Region
- To extend educational reach of academic centres and to initiate collaborative projects pertaining to oncology drug development and accessibility within the Asia-Pacific Region
- To improve the clinical trials infrastructure through continuous training and information sharing across committed clinical trials sites in the Asia-Pacific region.
- To further understand the opportunities and challenges of oncology drug development and accessibility within this region given its diversity in healthcare access and social-economic status.

Representative Publication(s):

- Loong, HH., Shimizu, T., Prawira, A., Tan, AC., Tran, B., Day, D., Tan, DSP., Ting, FIL., Chiu, JW., Hui, M., Wilson, MK., Prasongsook, N., Koyama, T., Reungwetwattana, T., Tan, TJ., Heong, V., Voon, PJ., Park, S., Tan, IB., Chan, SL., Tan, DSW. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group. ESMO Open. 2023 Jun;8(4):1-13.

6. Asia Pacific Coalition Against Lung Cancer (APCLC)

Background:

APCLC was formed in 2023 to empower Asia Pacific to overcome the burden of lung cancer, by addressing the region's specific needs and challenges. Founding members within the group include: (1) Dr. Herbert H. Loong, The Chinese University of Hong Kong, (2) Dr. Tho Lye Mun, Beacon Hospital, Malaysia, (3) Dr. Hidehito Horinouchi, National Cancer Centre Hospital, Japan, (4) Prof. Kwun Fong, The University of Queensland, Australia, (5) Dr. Daniel S. W. Tan, National Cancer Centre Singapore, (6) Dr. Kim Yeon Wook, Seoul National University Hospital, South Korea, (7) Dr. Thanyanan Baisamut, Mahidol, Thailand and (8) Dr. Sewanti Limaye, Sir H. N. Reliance Foundation Hospital, India.

Output(s):

- Implementation of lung cancer screening and detection, particularly amongst never smokers
- Advocating for and increasing awareness of lung cancer, particularly in never-smokers
- Championing for access to treatment – the right treatment, to the right patient, at the right time
- Engaging with the broader community including industry players and government bodies to advocate for universal health coverage
- To be independent, open and transparent in our efforts to ensure better care for patients

LEADERSHIP ROLES IN PROFESSIONAL SOCIETIES

Chair, International Affairs Committee, American Society of Clinical Oncology (ASCO) – 2024 – 2025

Chair, Asia Pacific Coalition against Lung Cancer (APCLC) – 2023 – Present

Chair-Elect, International Affairs Committee, American Society of Clinical Oncology (ASCO) – 2023 – 2024

Chair, Communication Committee, Connective Tissue Oncology Society (CTOS) – 2023 – 2024

Faculty and Curriculum Planner, American Society of Clinical Oncology (ASCO) Asia Pacific Leadership Development Program {Education planning for international training program for oncology leaders} – 2023 – 2025

Board of Directors, Connective Tissue Oncology Society (CTOS) – 2022 – 2024

Executive Committee Member, Asia Pacific Oncology Drug Development Consortium (APODDC) – 2021 – Present

Committee Member and Liaison, Asia-Pacific Regional Council, American Society of Clinical Oncology (ASCO) – 2019 – 2021

Committee Member, American Society of Clinical Oncology (ASCO) – 2018 – 2021

Member of the International Affairs Committee of ASCO providing insight and feedback on clinical oncology care from an international perspective

Strategic Committee Member, Connective Tissue Oncology Society (CTOS) – 2015 – Present

- Organizing Committee member of the “Sunrise in Tokyo” educational sessions at CTOS Annual Meeting 2019 to be held in Tokyo, Japan
- Strategic Committee member for CTOS 2019 meeting

Council Member, Hong Kong Neuro-Oncology Society (HKNOS) – 2015 – Present

- Member of governing council of HKNOS.

Council Member, Hong Kong Cancer Therapy Society (HKCTS) – 2017 – Present

- Member of governing council of HKCTS

Committee Member, International Association for the Study of Lung Cancer (IASLC) – 2017 – Present

Member of Communications Committee of IASLC involved in organizing and vetting dissemination of IASLC related information in the mass media

Inaugural Member, Immuno-Oncology Society of India – 2018 – Present

Founding Member, Asian Sarcoma Consortium (ASC), November 2015 – Present

POSTGRADUATE / NON-UNDERGRADUATE STUDENTS (Please refer to the Teaching File for further details)

Current CUHK Students (Total 1):

1. **PhD Student** – Mr. HAN, Fei,

Past CUHK Students (Total 4):

MPhil Student - Ms. KWONG Tsz Tung Anna, - Under co-supervision with Prof. Stephen L Chan

PhD Student - Ms. ZHANG, Yingjun, University - Under co-supervision with Prof Qian Tao

a. Research Topic: The role of histone deacetylation in the systemic management of soft tissue sarcomas

Global Physicians-Leadership Stream (MBChB) Student – Mr. KWAN, Sui Chun Sampson

Global Physicians-Leadership Stream (MBChB) Student – Mr. FUNG, Mong Yung

Non-CUHK Students (Total 2):

1. Higher Physician Trainee (HPT) in Medical Oncology, Hong Kong College of Physicians – Dr. Gordon C. H. Tang (2019-07 to 2022-07)
2. Supervisor to Hong Kong College of Physicians Medical Oncology Higher Trainee Dr. Kingsley Cheung (2023-07 to 2026-06)

INTERNAL SERVICE

Department

- Honorary Resident Specialist and Honorary Consultant, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong – March 2014 – present
 - Providing regular essential clinical service including in-patient and out-patient care of oncology patients and supervision of trainee physicians
 - Providing inter-hospital consultations for cancer patients in North District Hospital, Hong Kong
 - Senior on-call and consultation services for Department of Clinical Oncology, Prince of Wales Hospital
- Member, Department of Clinical Oncology, CUHK – March 2014 – present
- Member, Postgraduate Students Committee, Department of Clinical Oncology, CUHK – September 2016 – present
- Internal Examiner for PhD Defense of PhD Student (Mr. Mao) – August 2016

Faculty & College

- Founding Convener/Chairman, CUHK/Prince of Wales Hospital Adult Sarcoma Multidisciplinary Tumour Board, January 2014 – Present
 - Formed and coordinate multidisciplinary sarcoma patient care for CUHK and Prince of Wales Hospital, Hong Kong
 - Chair of regular biweekly Adult Sarcoma Multidisciplinary Tumour Board meetings held in Prince of Wales Hospital, in collaboration with physicians from over 8 different associated disciplines
- Category 2 Member, Department Board of Medicine & Therapeutics, Jan 2017 – Present

- Assistant Professor Representative to Faculty Board, Faculty of Medicine, CUHK - May 2014 – June 2015 and academic year 2018/19
 - Was elected by fellow Assistant Professors to the Faculty Board of Faculty of Medicine, CUHK to represent their interests for 2 separate terms in 2014-2015 and 2018-2019
- Ethics Committee Member, Phase 1 Panel, Joint CUHK-PWH Clinical Research Ethics Committee – Jan 2018 – present
 - Provide critical review of clinical research ethics applications, in particular to phase 1 clinical trials
- Executive Committee Member, Phase 1 Clinical Trial Centre, CUHK, Jan 2017 – Present
- Internal Examiner for MPhil Defense of MPhil Student (Ms. Fan) – Sep 2019
- College Teaching Staff – CW Chu College, May 2015 – Present
- Mentor for medical students within CW Chu College, Jan 2016 – Present
 - Provide mentorship to medical students within CW Chu College through regular exchange with the faculty and during meetings within CW Chu College

EXTERNAL SERVICE

Academic

- External Examiner, Faculty of Medicine (for the Degree of Doctor of Medicine), The University of Hong Kong, April 2023
- Grant Application Reviewer, United Kingdom Research and Innovation Future Leaders Fellowships, (Grant Reference MR/T043385/1 | Applicant: Dr. Donna Graham, Christie NHS Foundation Trust), January 2019
- Clinical Mentor, DreamCatchers MedTech Hackathon 2016, The University of Hong Kong, August 2016
- Poster Judge & Visiting Academic, the 2nd International Sarcoma Symposium (Organized by Mt. Sinai Hospital, University of Toronto), Toronto, ON, Canada, June 2016
- External Examiner, Department of Pathology (for the programme of MMedSc in Pathology), The University of Hong Kong, September 2015

International Clinical Trials Responsibilities

- International Steering Committee Member – Johnson & Johnson
 - A study of JNJ-90301900 in combination with chemoradiation followed by consolidation immunotherapy for non-small cell lung cancer (NSCLC) (CONVERGE)
 - Clinicaltrials.gov Identifier: NCT06667908
- International Steering Committee Member – Boehringer-Ingelheim
 - BRIGHTLINE-4: A phase III open-label, single-arm, multicentre study to assess the safety and efficacy of brigimadlin (BI907828), an MDM2-p53 antagonist, in patients with treatment naïve or pre-treated advanced dedifferentiated liposarcoma

- Clinicaltrials.gov Identifier: NCT06058793
- International Steering Committee Member – Novartis
 - KontRAsT-02: A phase III trial investigating the efficacy and safety of the KRAS^{G12C} inhibitor JDQ443 vs. docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC
 - Clinicaltrials.gov Identifier: NCT05132075
- International Steering Committee Member – Eli Lilly and Company
 - A Study of Selpercatinib (LY3527723) in Participants with Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)
 - Clinicaltrials.gov Identifier: NCT04194944
- Asia-Pacific Steering Committee Member and Asia-Pacific Chief Principal Investigator – Athenex Inc.
 - A Pilot Study of Oraxol in Angiosarcomas
 - Clinicaltrials.gov Identifier: NCT03544567

Advisory Board / Consultancy / Speakers' Bureau (within the last 3 years from July 2022 – July 2025)

Advisory Board member to numerous organizations and pharmaceutical industry partners including:

- Boehringer-Ingelheim
- Celgene
- Eli-Lilly
- George Clinical
- Illumina
- Novartis
- Merck Sereno
- Takeda
- Emerald Clinical trials

Speakers' Bureau to numerous organizations and pharmaceutical industry partners including:

- AbbVie
- Amgen
- Bayer
- Eisai
- Eli-Lilly
- Guardant Health
- Novartis

Travel Support from numerous organizations and pharmaceutical industry partners including:

- Bayer
- Boehringer-Ingelheim
- MSD
- Novartis
- Pfizer

Research funding received from numerous organizations and pharmaceutical industry partners including:

- MSD
- Mundipharma

- Novartis

Professional

- Board Member, Drug & Poisons Board, Department of Health, Government of the Hong Kong SAR (Regular board member tasked with vetting drug registration and clinical trials certificate issuance in Hong Kong) 2018 – 2023
- Member, Liaison to Asia-Pacific Regional Council, American Society of Clinical Oncology (ASCO), 2019 - Present
- International Affairs Committee (IAC) Member, American Society of Clinical Oncology (ASCO), 2018 – Present
- Education Committee Member, International Association for the Study of Lung Cancer (IASLC), 2019 - Present
- Communications Committee Member, International Association for the Study of Lung Cancer (IASLC), 2018 – 2019
- Medical Expert, Drug & Poisons Board, Department of Health, Government of the Hong Kong SAR (Professional consultations/opinions at irregular intervals for registration of drugs and clinical trials) May 2015 - Present
- Working Group Member, Cancer Prevention Working Group, Department of Health, Government of the Hong Kong SAR, June 2016 – Present
- Working Group Member, Response Assessment in Neuro-oncology (RANO) Working Group in Steroids in Neuro-oncology, January 2016 – Present
- Volunteer Medical Professional/Educator, Health Volunteer Overseas, (including a medical education mission to Hue Central Hospital and Hue University of Medicine & Pharmacy, Hue, Vietnam for teaching and training of oncologists and medical students), March 2015 - Present
- American Society of Clinical Oncology (ASCO) Multidisciplinary Cancer Management Course (MCMC) Working Committee Member, June 2013 – May 2015
- Medical Advisor, Hong Kong GIST Union, December 2014 – Present

Extra-curricular

- Specialist Flight Lieutenant (Medical), Hong Kong Air Cadet Corps, January 2008 – Present
- Parent Volunteer, 1st Canadian Hong Kong Scouts Group, September 2018 - Present